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Virtually all cervical cancer cases worldwide are caused by oncogenic (high risk) HPV 
genotypes, with 70% attributable to the two dominant types, HPV16 and 18.  The HPV 
replicative cycle relies on the capability of keratinocytes to undergo differentiation in 
the stratified epithelia. However, persistent mucosal high risk HPV infections can result 
in abortion from the productive replication cycle and deregulated viral oncogene (E6 
and E7) expression, driving carcinogenesis. A group of genes known as CTAs normally 
exhibit testis-specific expression in healthy individuals. The immune privileged 
characteristic of testis has allowed the identification of cancer testis antigens (CTAs) 
with aberrant expression in tumours as potential biomarkers for immunotherapeutic 
approach to cancer treatment. A component of the meiotic synaptonemal complex, 
SYCP2 is strongly upregulated in HPV+ compared to HPV- cancers and normal epithelia. 
In this project, we aim to measure SYCP2 expression in HPV+ cancer cell lines and 
determine the effect of gene knockdown using siRNA or gene knockout using CRISPR-
Cas9. An SYCP2 qPCR assay was established and optimised and SYCP2 overexpression 
was confirmed in HPV16+ cell lines but intriguingly not in HeLa (HPV18+), suggesting 
some key cellular differences between these two genotypes. Moreover, cell viability did 
not seem to be affected by SYCP2 depletion, although complete gene silencing was not 
achieved. We also used next-generation amplicon sequencing to assess CRISPR gene 
editing efficiency of SYCP2, indicating the need for improved enrichment of transfected 
cells using fluorescence-activated cell sorting (FACS). This study has obtained data that 
complies with past studies on the upregulation of SYCP2 expression which will allow 






1.1 Human papillomavirus  
1.1.1 Structure and genome 
The Papillomaviridae is a family of double-stranded DNA viruses that demonstrate 
strong epitheliotropism and are known to infect many mammalian species and others 
such as birds and reptiles (Bravo, de Sanjosé and Gottschling 2010; Van Doorslaer et al. 
2018). Human papillomavirus (HPV) comprises a large group of diverse viruses that 
exclusively infect the keratinocytes of mucosal and cutaneous stratified squamous 
epithelia in humans (Orav et al. 2015). Regions such as the genitals, anus and oropharynx 
are usual targets of the mucosal targeting HPVs (Tuominen et al. 2018). The majority of 
humans would have been colonised by several HPVs at some point in their lifetime, 
causing asymptomatic infections which are generally eliminated by the immune system 
(Bravo and Felez-Sanchez 2015). HPV triggers host cell proliferation as part of its 
infectious cycle, and thus HPV infection may lead to benign clinical manifestations such 
as skin and genital warts (papilloma). More rarely, HPV can become integrated into the 
host genome. This disrupts the regulation of both virus and host genes and can thus lead 
to cancer development through uncontrolled expression of viral proto-oncogenes 
(Handisurya, Schellenbacher and Kirnbauer 2009).  
 
To date, more than 200 HPV genotypes are known (Schiffman et al. 2016) and are 
categorised into five phylogenetic genera based on disease association, replicative cycle 
features and DNA sequencing data, designated as alpha, beta, gamma, mu and nu 




infect mucosal epithelia, whereas the beta-HPVs generally infect cutaneous epithelia 
(Tomaić 2016).  
HPVs are non-enveloped viruses that are about 60nm in diameter, with an 8-kilobase, 
circular double-stranded DNA (dsDNA) genome contained within an icosahedral protein 
capsid comprised of 72 pentameric capsomers (Sapp 2013; OMS 2007). All HPV types 
include approximately eight open reading frames (ORFs) in their genome, which can be 
divided into three main regions: early, late and a non-coding segment known as the long 
control region (LCR) or the upstream regulatory region (URR) (Zheng and Baker 2006; 
OMS 2007). The well-characterised structure of HPV16 genome is shown in Figure 1.2. 
Individual HPV types are distinguished from others by having at least 10% difference in 
the nucleotide sequence of L1 ORF (Liu et al. 2017). Those with differences between 1-
Figure 1.1 The phylogeny of HPV 
Illustration of the five HPV genera and the evolutionary relationship between different HPV 





10% (within the same HPV types) are known as HPV variant lineages (Harari, Chen and 
Burk 2014).  
 
The viral genome mostly encodes six regulatory proteins from the early region: E1, E2, 
E4, E5, E6 and E7. Plus, two structural proteins from the late region: L1 and L2, the major 
and minor capsid proteins, respectively (Graham 2010; Depuydt et al. 2016). The LCR 
region covers approximately 10% of the HPV genome, containing the origin of 
replication and many DNA recognition sites for both host and viral transcription factors. 
These are essential for regulating gene transcription from the early and late promoters 
(Zheng and Baker 2006). The genome also comprises of a keratinocyte-specific enhancer 









Figure 1.2 HPV16 genome structure 
Illustration of HPV16 genome with 7904 bp, comprising of three main segments. The early region 
that encodes seven ORFs E1, E2, E4, E5, E6, E7 and E8. The late region encodes two ORFs, L1 and 
L2. The LCR is a non-coding region. The ORFs in blue expresses capsid proteins. The pink ORFs 
encodes HPV16 oncoproteins and the green ORFs expressions proteins vital for HPV replication 





Both E1 and E2 protein participate in viral genome replication where E1 oligomers act 
as an ATP-dependent helicase to separate the dsDNA and transcription factors are 
encoded by the E2 ORF. Heterodimers formed by E1 and E2 join the cellular replication 
machinery at the origin of replication, from which bidirectional DNA synthesis is 
triggered (Reinson et al. 2013; Harari, Chen and Burk 2014). Due to messenger RNA 
(mRNA) splicing, E4 protein exists as an E1^E4 fusion protein and is abundantly 
expressed in productive lesions, especially in cells within the upper epithelial layer, 
suggesting a role in genome amplification to assist virus synthesis. It has also been 
shown to function in viral release both in vivo and in vitro as its N-terminal leucine-rich 
motif (LLXLL) associate with and reorganises the cytokeratin network (Doorbar 2013; 
Egawa et al. 2017). Furthermore, in some HPV types (HPV18, 31 and 11) analysed in 
human primary foreskin keratinocytes where there is disruption to the keratin binding 
motif, genome amplification is impaired. However, the disruption does not always 
interfere with the viral replicative cycle across all HPV types. (Nakahara et al. 2005; 
Egawa et al. 2017). 
 
E5 proteins are not expressed by all HPV genera. For example, beta-, gamma- and mu-
HPVs do not contain the E5 ORF but alpha-HPVs do (Di Domenico et al. 2009). This 
indicates that it is not important for the completion of the HPV replication cycle. Instead, 
it may provide some form of advantage during infection. E5 proteins are found in the 
suprabasal layer and functions in apoptosis inhibition and upregulation of transcription 
factors to maintain active cell division (Müller et al. 2015). Also, it can reduce the 
expression of major histocompatibility complex (MHC) I on the surface of infected basal 
cells, inhibiting antigen presentation to T-cells. Thus, E5 may help to evade the immune 




Expression of E6 and E7 is essential for the HPV replicative cycle. Early studies have 
shown increased mRNA level in the lower to mid-upper epithelial layers  (Stoler et al. 
1992) but reduction in E6 and E7 biomarker expression was seen in the upper epithelial 
layers (Middleton et al. 2003). These results indicate that E6 and E7 proteins are 
required in the early stages of HPV replication. E6 has been shown to play a role in 
maintaining episomal genome (Park and Androphy 2002).  
 
Upon E6 expression, the ubiquitin-proteasome system is hijacked to facilitate rapid p53 
degradation by forming a trimeric complex consisting of p53, E6 and E6AP (an E3 
ubiquitin ligase). The loss of p53 function is detrimental for the cells, it results in lack of 
apoptosis regulation, increased genomic instability, disruption in the cellular response 
to DNA damage and other cellular functions (Ozaki and Nakagawara 2011). E6 also 
interferes with many other biological functions such as the cell cycle, G1 checkpoint 
activity is lost very early on in transformed cells expressing E6 (Yim and Park 2005).  
 
Non-phosphorylated retinoblastoma (RB) behaves as a transcriptional repressor by 
binding at promotor regions containing E2F (transcriptional factor) sites. E7 protein can 
bind to the ‘pocket domains’ of non-phosphorylated RB and cause degradation through 
the ubiquitin-proteasome pathway. This result in the release of the transcriptionally 
active form of E2F as the association between RB and E2F is lost. Consequently, 
transcriptions induced by E2F are upregulated including key components of the cell cycle 
(CDK2, cyclins A and E). Causing stimulation of the checkpoint between G1 and S phase 
in basal cells that undergoes differentiation. Therefore, it allows the expansion of cells 
undergoing DNA replication in the basal layer (Yim and Park 2005; Tomaić 2016; Graham 




keratinocytes. This is accomplished by destabilising a RB related pocket protein, p130 
which is known to prevent S phase re-entry (Banerjee et al. 2011). 
 
1.1.2 The infectious cycle of HPV 
Upon micro-trauma of the stratified epithelium, infectious HPV particles come into 
contact with the basal keratinocytes where they release the HPV genome into the host 
cells. This genome is then transported to the nucleus for transcription and replication. 
The differentiation stages of the multi epidermal layers is relied on by the process of 
HPV replication cycle (Reinson et al. 2015).   
 
In vivo, HPV infections are established through initial binding between L1 proteins and 
the heparin sulphate proteoglycans (such as Syndecan-1) on the extracellular basement 
membrane. This induces a cyclophilin B-induced conformational change where it 
exposes the N-terminus of L2 proteins on the surface, allowing removal of one of its 
nuclear localisation signal (NLS) domains via cleavage by cellular furin protease (Graham 
2017). The consensus furin cleavage motif (R-X-K/R-R) is found conserved across 
numerous papillomavirus types (Buck, Day and Trus 2008; Day, Lowy and Schiller 2008; 
Wang and Roden 2013). Further conformational change of the capsid occurs which may 
lower the affinity of L1 for heparin sulphate proteoglycans and expose particular binding 
sites on L1, allowing interactions with yet to be identified secondary receptors on the 
surface of basal keratinocytes. This prompts internalisation of the viral particles via 
tetraspanins-mediated endocytosis (Richards et al. 2006; Horvath et al. 2010). In recent 
studies, there have been some indications that epidermal growth factor receptors 




2006) are potential candidates as secondary receptors that facilitate the entry of HPVs. 
Interestingly, studies of cells with furin deficiency and presence of furin inhibitors in vivo 
and in vitro demonstrated low level of infection activity across various papillomavirus 
types (Wang and Roden 2013). Thus, indicating the importance of truncated L2 in 
inducing effective infection.   
 
Upon entry, HPVs are transported in vesicles through the early endosomes, late 
endosomes/lysosomes, trans-Golgi-network and the endoplasmic reticulum before they 
are directed to the nucleus where they enter the nuclear pores after nuclear envelope 
breakdown in mitosis (Aydin et al. 2014; Aksoy, Gottschalk and Meneses 2017). Viral 
capsids are degraded in the endolysosomal system and L2 proteins are known to 
mediate trafficking of the viral genome to the trans-Golgi-network (Aksoy, Gottschalk 
and Meneses 2017). Once the genome is in the nucleus, it has been shown to reside at 
the PML oncogenic domains (PODs) where viral gene transcription are initiated 
(Broniarczyk et al. 2018). 
 
Firstly, HPV undergoes an initial amplification of its genome to achieve a viral copy 
number of approximately 50 to 100 copies per keratinocyte (Stanley 2012). Only the 
early transcripts are transcribed at this point, primarily for their role in genome 
replication. Once the infection is established, the viral copy number is maintained at a 
low level in the basal layer and transcription also occurs at a low rate (Bienkowska-Haba 
et al. 2018).  
 
As the infected cell divide into two daughter cells, the one that has initiated 




whilst carrying the viral genome. It was confirmed in a study (Oldak et al. 2004) that E2-
mediated integrin suppression was required for the detachment of infected 
keratinocytes from the basement membrane. In particular, high concentrations of β4-
α6 integrin dimers are found in the basement membrane (Oldak et al. 2004). As 
migration occurs, HPVs enters the final stage of its replication cycle, the vegetative 
amplification phase. It induces G2 arrest in the proliferating keratinocytes (Wang et al. 
2009) and uses them to extensively replicate its viral genome. This is an unusual strategy 
for virus replication. It could be the case that HPV is unable to hijack the replication 
machinery whilst the host undergoes DNA replication. However, by inducing G2 arrest, 
it would provide a chance for HPV to perform rapid and efficient amplification without 
any competition. 
 
In the upper epithelial layers, the level of viral proteins increases significantly, leading 
to amplification of thousands of genome copies per cell (Kajitani et al. 2012). In the 
terminally differentiated cells, capsid proteins (L1 and L2) are synthesised for the 
assembly of virions. The viral genomes are packaged into the progenitor virions and are 
released from the keratinocytes in the cornified epithelial layer (mostly the upper layer) 
(Kajitani et al. 2012).  
 
The DNA damage response pathway plays a major role in genome amplification and the 
expression of late genes. Ataxia telangiectasia mutated (ATM) and ataxia telangiectasia 
and Rad3-related (ATR) kinases are two important sensors of DNA damage within cells 
and regulators of the repair mechanism (Graham 2017). Early in the replication cycle, 
E1-mediated ATM activation may contribute to the maintenance of HPV genome copy 




were contained within the replication factories that are formed when E1 and E2 come 
together, facilitating the viral genome replication (Blackford and Jackson 2017). E7 has 
been demonstrated to activate the ATM pathway required for the vegetative 
amplification phase in differentiated epithelial cells (Banerjee et al. 2011).  
 
HPV is capable of sustaining an infection for a prolonged period by retaining its episomal 
genome within the epithelial basal layer whilst expressing limited viral components. One 
of the ways to evade immune detection is through the expression of E2 protein, along 
with cellular proteins such as SMCX (a methylase), EP400 (a component of the TIP60 
histone acetyltransferase complex) and Brd4 (an E2-binding bromodomain protein). 
Together, they transcriptionally repress the early promoter gene by altering the 
chromatin conformation (Smith et al. 2014; Graham 2017) which reduces the expression 
level of E6 and E7. 
 
In HPV 1, 8, 16 and 31, E8^E2 fusion protein interacts with the corepressor complexes 
which act as a negative regulator of viral replication and transcription. Notably, the 
protein also plays a critical role in limiting the productive replicative cycle of HPV16. 
Therefore, the expression level of E8^E2 protein may determine if the infection 
progresses or becomes latent (Dreer, van de Poel and Stubenrauch 2017).  
 
HPVs can also compromise the innate immune system in infected keratinocytes by 
suppressing synthesis and signalling of interferons (IFNs) such as IFN-⍺ and IFN-β. IFNs 
are essential for the control of viral infection. Cell deaths are not observed from the 
replication cycle and the assembly of virions which leads to lack of inflammation. 




suggesting that the antigen-presenting cells such as Langerhans cells and stromal 
dendritic cells are not activated and migrate to the site of infection. As a result, the virus 
essentially delays the activation of adaptive immunity and remain undetectable to the 
host defence system (Stanley 2012).  
 
1.1.3 HPV and cancer 
1.1.3.1 HPV prevalence  
Globally, HPV is the most frequent sexually transmitted infection and it has been 
proposed that about 75% of men and women who are sexually active will be affected by 
genital HPV infection at some stage in their life (Nejo, Olaleye and Odaibo 2018). 
Approximately 11-12% of women worldwide with normal cytology were tested positive 
for HPV in a meta-analysis of cervical HPV prevalence (Bruni et al. 2010) involving 194 
studies and test subject of over one million women. However, the prevalence varied 
considerably between different regions of the world. It is significantly higher in Eastern 
Europe (21.4%), Latin-America (16%) and rises to above 30% for Eastern Africa and the 
Caribbean. Regions with the lowest rate include Northern America (4.7%) and Western 
Asia (1.7%) (Formana et al. 2012).  
 
Another worldwide meta-analysis (Guan et al. 2012) including 423 PCR-based studies, 
compared 266,611 women with normal cytology and 106,625 with cervical 
abnormalities. The results coincide with the former meta-analysis where 12% of women 
with normal cytology were HPV-positive. The study also showed a strong increase of 
prevalence in HPV positivity rate as lesion severity rises, reaching the highest of 93% in 




invasive cervical cancer (ICC) were tested positive for HPV, which is the second-highest 
rate among all cervical disease grades (Formana et al. 2012). There was also a significant 
increase in HPV16 detection among HPV-positive women as cervical lesion severity 
increases, with the highest of 63% in women with ICC. 
 
1.1.3.2 HPV-related cancers 
The majority of cutaneous and mucosal HPV types, including HPV 6 and 11 within the 
alpha genus are classified as low-risk, causing respiratory papillomatosis and genital 
warts which are not life-threatening and rarely cause neoplasia (Danielewski et al. 2013). 
They are usually cleared up by the host immune system without any intervention within 
two years (Salman et al. 2017).  
 
On the contrary, high-risk HPV types including HPV16, 18 and 45 are well-established 
cancer-causing agents in areas including the cervix, anus, penis, vulva, vagina, and the 
oropharynx. HPV16 and 18, the two most carcinogenic HPV genotypes are accountable 
for about 70% of cervical cancer worldwide, with HPV16 being the predominant 
causative agent (Pirog et al. 2014). HPV16 is also the most prevalent type in HPV+ head 
and neck cancers whereas other high-risk types are hardly detected (Tomaić 2016).  
 
Cervical cancer is the most common HPV-induced cancer and a massive health burden 
globally. It was ranked fourth for incidence and mortality for women in a global cancer 
statistic report (GLOBOCAN) produced by the International Agency for Research on 
Cancer in 2018 (Bray et al. 2018). Notably, it was the leading cause of cancer-induced 
mortality in 42 countries out of 185. It has been estimated that by 2040, the number of 




569,000 in 2018. Mortality rate would also increase to over 450,000 per annum globally, 
compared to 311,000 in 2018 (Bray et al. 2018). Notably, the less developed regions 
contribute a major portion to these statistics. The mortality age-standardised rate per 
100,000 females in low/medium human development index (HDI) regions were 18.2 in 
comparison to 4.1 in high/very high HDI regions (Bray et al. 2018). 
 
1.1.3.3 HPV genome integration 
Genomic integration represents an abortion of the HPV replication cycle; it is frequently 
associated with truncations or deletions of viral genes (Pinidis et al. 2016) and once 
integrated into the host genome, the viral genome can no longer be amplified or 
packaged and transmitted to a new host. Thus, it is non-productive for the virus. HPV 
integration is detected in premalignant cervical lesions, but is more frequently detected 
in invasive carcinoma (McBride and Warburton 2017). Integration is thought to promote 
oncogenesis by deregulating the expression of E6 and E7 genes to enhance proliferation, 
disruption of cell cycle checkpoints and triggers progressive genomic instability 
(McBride and Warburton 2017).  
 
A model suggested that cervical inflammation could promote HPV genome integration 
in cervical carcinoma (Williams et al. 2011). It is thought that the generation of 
inflammation-induced reactive oxygen and nitrogen species could result in DSBs in both 






1.1.3.4 HPV oncoproteins 
E6 and E7 are the two predominant proteins that contribute to the oncogenesis of high-
risk HPV type-induced cancers. They are transcribed as a single bicistronic transcript due 
to being located in the same ORF (Jiang and Yue 2013). Their contribution toward 
carcinogenesis includes immortalisation of proliferating cells and cell cycle disruption 
through degradation or inactivation of essential cell cycle regulatory components 
including the tumour suppressor proteins p53 and Rb (Vishnoi et al. 2016; Jing et al. 
2014). High levels of E6 and E7 expression have been demonstrated to induce polyploidy 
by disrupting the G2-M-phase transition in primary human keratinocytes (Patel et al. 
2004).  
 
Before host genome integration, low levels of E6 and E7 are found in the basal cells 
(Nees et al. 2000), mostly due to the positioning of E2 binding sites within the E6/E7 
promoter region. Hence, it was proposed that the breakpoint of HPV episome occurs at 
the E1 and E2 gene which corresponds to the transcription repression effect of E2 on E6 
and E7. Therefore, the loss of E2 expression induced by integration directly result in 
upregulation of E6 and E7 as cancer progresses (Francis, Schmid and Howley 2000). 
However, this is not always the case. There are also many other HPV-associated cancer 
(particularly HNSCC), in which the HPV appears to remain episomal. 
 
Expression of E6 and E7 oncoproteins provide a suitable setting for DNA replication in 
differentiating epithelium which drives oncogenesis. However, tumour development is 
merely a side effect of HPV infection. The ability of host cells to replicate is an advantage 





1.2 Cancer testis antigens 
1.2.1 CTA expression  
CTA comprise a group of genes that normally demonstrate exclusive expression in the 
germ line tissues such as testis, placenta and ovary of healthy individuals. However, low 
level expression of CTAs has also been found in some somatic tissues or immune-
privileged areas. CTAs that are expressed in testis and no more than two other tissue 
types are classified as testis selective. Some CTAs are termed testis brain restricted when 
it is expressed in testis and the central nervous system. CTAs that are limited to the testis 
are testis restricted (Whitehurst 2014).  
 
To date, there are over 270 CTA genes (from CTDatabase) that are divided into two main 
categories, over 100 of which are cancer testis-X (CT-X) antigens that are encoded on 
the X chromosome and another 100 genes are located on autosomes, producing the 
non-X CTAs (Bode et al. 2014; da Silva et al. 2017), with the remainder found on the Y 
chromosome (Dobrynin et al. 2013). X-CTA genes are predominantly expressed on the 
spermatogonia in normal testes. Whereas, non-X CTAs are expressed on spermatocytes 
that are in the late stages of germ-cell differentiation (Fratta et al. 2011).  
 
The discovery of CTAs and their increased expression in a broad spectrum of cancers 
were significant in tumour immunotherapy. The absence of human MHC-I molecules in 
germ cells implies that they cannot undergo antigen presentation to T cells (Bruggeman 
et al. 2018). Hence, CTA expressed in tumour cells can be regarded as neoantigens, thus 
triggering humoral and cell-mediated immune responses which are strictly cancer-




biomarker targets for immunotherapeutic approaches to cancer treatments such as 
adoptive T-cell transfer with chimeric T cell receptor and CTA vaccine therapy (Fratta et 
al. 2011; da Silva et al. 2017).   
 
The aberrant expression of CTAs in tumours is an intriguing concept, the underlying 
mechanisms responsible for the upregulation is yet to be fully understood. Whereas in 
normal and neoplastic cells, it is suggested that epigenetic events play a major role in 
CTA expression. Histone acetylation and DNA methylation are regarded as two of the 
most well-characterised factors (Fratta et al. 2011). Most of CTAs in normal somatic cells 
contain methylated CpG islands in their promoter region which repress expression. 
However, they are activated by demethylation during spermatogenesis in germ line cells. 
Another epigenetic modification is deacetylation of histone, leading to chromatin 
compaction which supresses the activity of transcription factors and RNA polymerases. 
Thereby, acetylation and inhibition of deacetylation enzymes can stimulate expression 
of CTAs (Karpf 2006; Salmaninejad et al. 2016). Transfection experiments with reporter 
genes driven by methylated/unmethylated CTA promoters in vitro were the decisive 
evidence for association between hypomethylated CTA promoters and their elevated 
expression (Luca Sigalotti et al. 2002; L. Sigalotti et al. 2002). 
 
1.2.2 Functional role of CTAs in cancer  
In previous studies, several CTAs have been suggested to play a positive regulatory role 
in signalling pathways that are often hyperactive in cancerous cells. An example is 
ATPase Family AAA Domain Containing 2 (ATAD2) protein which behaves as a cofactor 




it has been proposed that the protein may promote tumourigenicity by enhancing the 
MYC-dependent transcription, leading to disruption of several key cellular processes 
such as cell growth, DNA damage response and genomic instability (Adhikary and Eilers 
2005). Reduction of ATAD2 level in tumour cells impedes with cellular proliferation by 
preventing S-phase entry (Whitehurst 2014). Furthermore, its high expression level 
corresponds with poor prognosis in breast cancer patients (Ciró et al. 2009; 
Kalashnikova et al. 2010).  
 
PRAME (melanoma antigen preferentially expressed in tumours) is another CTA that is 
overexpressed in human malignancies including melanomas, head and neck cancers and 
chronic leukaemia (Whitehurst 2014). A study identified PRAME as a dominant repressor 
of retinoic acid receptor signalling (Epping et al. 2005). It prevents intrinsic ligand 
(retinoic acid)-receptor interaction by occupying the receptor binding site. This 
signalling pathway is particularly important for proliferation arrest, differentiation and 
apoptosis.  Thereby, disruption of this pathway is frequently observed in cancers and it 
was suggested that upregulated expression of PRAME provided growth or survival 











1.3 Synaptonemal complex protein 2 
1.3.1 Meiotic function 
Synaptonemal complex protein 2 (SYCP2) is a meiotic-specific protein of molecular mass 
of 175KDa and it has been observed to be overexpressed in HPV-related cancers. 
However, it is not officially categorised as a CTA like its family member SYCP1 despite 
their almost exclusive expression in the testis.  
 
To date, not much information is known about this protein. However, it is believed to 
be involved in chromosome linkage through the synaptonemal complex (SC) and to drive 
meiotic prophase I. Prophases are generally divided into five substages, leptotene, 
zygotene, pachytene, diplotene and diakinesis. During leptotene, homologous 
chromosomes are paired up, SYCP2 and SYCP3 form a heterodimeric structure at the 
interchromatid domain called lateral elements (LEs). Before synapsis of homologues, LEs 
are referred to as axial elements (AEs) (Pelttari et al. 2001; West et al. 2019). In zygotene, 
the transverse filaments (TFs) comprises of SYCP1 acts as a linker between the two LEs 
and another component of the SC, known as central element (CE). CEs are primarily 
composed of proteins such as synaptonemal complex central element protein (SYCE) 1, 
2, 3 and testis expressed protein 12 (TEX12) (Seo et al. 2016). Together, they form the 
zipperlike structure known as SC, shown in Figure 1.3. Complete assembly occurs in 
pachytene where synapsis is complete and in diplotene, the disassembly is initiated 
(Pelttari et al. 2001; Fraune et al. 2012). In all diploid organisms where SCs are found, 













A common feature of DNA binding proteins is Ser/Thr-Pro and Ser/Thr-Ser/Thr motifs, 
allowing binding with DNA at the minor groove in a non-sequence-specific manner. 
SYCP2 in mice contains two large clusters of these motifs near its C-terminus which are 
proposed to form a short coiled coil domain (Offenberg et al. 1998). This domain is 
conserved throughout evolution and is required for interaction with SYCP3 and 
chromatin. In mice SYCP2-/- spermatocytes with deleted coiled coil region, SYCP3 form 
large protein aggregates in the nucleus but incorporation into the SCs was not detected 
(Yang et al. 2006). This confirms that presence of SYCP2 is necessary for SYCP3 
localisation to the axial chromosome core. Furthermore, lack of SYCP2 also impairs LE 
formation. Silver nitrate is used as a stain to identify LEs and paired LEs. Electron 
microscopy reveals no silver-stained LEs in SYCP2-/- spermatocytes, structures that 
resemble SC with alignment between chromatins and CE-like structures were formed 
instead. However, the structure does lack the electron dense LEs that are generally 
Figure 1.3 Structure of synaptonemal complex 
Illustration of components that make up the synaptonemal complex. The transverse filament links 
the LE and CE together. SYCP2 and SYCP3 of the lateral elements interact with the homologous 





observed in wild-type spermatocytes (Yang et al. 2006). In SYCP3-deficient meiotic cells, 
no silver-stained LEs were detected, illustrating that SYCP3 is critical for SYCP2 
recruitment, LE assembly and potentially plays a role in anchoring LEs to meiotic 
chromatin (Pelttari et al. 2001).  
 
The formation of SC is indispensable for the effective segregation of homologous 
chromosomes during the first meiotic division. In male mice, depletion of SYCP2 or 
SYCP3 has been found to result in severe synaptic defects and apoptosis of 
spermatocytes, resulting in infertility (Yang et al. 2006). However, the effect is fairly mild 
in SYCP3-deficient females, the females become sub-fertile with reduced litter size, 
caused by increasing number of aneuploidies (Yuan et al. 2002; Yang et al. 2006). This 
indicates that mice may exhibit sexually dimorphic response towards meiotic disruption 
caused by the loss of LE proteins (Alves et al. 2017). Association between defective SC 
formation and non-lethal aneuploidy such as Down syndrome have been demonstrated 
(Seo et al. 2016).  
 
In mammalian meiotic cells, the sister chromatids must remain attached during first 
round of meiotic division. This is mainly achieved by a cohesin complex comprised of 
meiotic-specific proteins and those that are also present in mitotic cells (Kouznetsova et 
al. 2005). Additional functions of LEs were proposed in establishing and/or maintenance 
of cohesion between sister chromatid. Stromal antigen 3 (STAG3) is a component of the 
cohesin complex and was observed to colocalise with SYCP3 in diplotene spermatocytes 
and pachytene/late diplotene oocytes using immunostaining (Prieto et al. 2001). 
Interestingly, STAG3, SYCP3 and SYCP2 all seem to disappear within the first week of 




positive filaments were discovered almost only at sites where SYCP3 were still detected 
on chromatin (Kouznetsova et al. 2005). Dictyotene is unique to oogenesis, causing 
complications when making direct comparison to male germ cells. Although, analysis of 
cells at prometaphase I during spermatogenesis also shows a fragmented cohesin core 
(Prieto et al. 2001). The observations indicate a possible mechanistic link between the 
loss of the two LE proteins and the cohesin core.  
 
It is proposed that SYCP3 may have the ability to modulate integrity of cohesin core. 
SYCP3-deleted spermatocytes have shown cohesin core formation in zygotene and 
pachytene (Pelttari et al. 2001). However, as cells advanced into the diplotene stage, 
the STAG3 cohesin cores became highly fragmentated. This confirms the need of LE 
proteins for desynapsed STAG3 cohesin core integrity, as well as preventing premature 
disassembly of the cohesin core complex (Kouznetsova et al. 2005). Together with SC, 
both complexes contribute to the organisation of the chromosome axis during meiotic 
prophase I and ensure proper chromosome segregation. 
 
The N-terminus of mouse SYCP2 seems to associate with the centromere region during 
meiosis I. This is achieved by an ARLD (armadillo-repeat-like-domain) subdomain 
interacting with two components of the centromere, CENP (centromere protein) J and 
CENP F (Feng et al. 2017). Given the interaction between the C terminus of SYCP2 and 
SYCP3/SYCP1, along with centromere association, it is rational to postulate that SYCP2 
may behave as a bridge between SC and the centromere. This idea is consistent with the 
lack of SYCP1 immunofluorescence and gradual disappearance of SYCP3 observation in 





HORMA domain-containing protein (HORMAD) 2 is a CTA that act as an important 
regulator of double strand breaks (DSBs) and crossover formation in meiosis (West et al. 
2019). It is proposed that the chromosome axial core proteins recruit HORMADs to the 
axis via their HORMA domain-binding closure motifs, which are later removed by AAA+ 
ATPase, thyroid hormone receptor interactor 13 (TRIP13) as germ cells enter the 
pachytene stage. This prevents further DSBs and allowing recombination of homologues 
(Wojtasz et al. 2009). It has been shown that SYCP2 interacts with HORMAD2, suggesting 
a possible a role of SYCP2 in HORMAD2 recruitment.  
 
1.3.2 Overexpression of SYCP2 in HPV-positive cancers 
Several gene expression profiling studies of HPV-positive cancers have shown 
upregulation of SYCP2, along with other characterised CTAs (Slebos et al. 2006; Martinez 
et al. 2007; Masterson et al. 2015). In one of the studies (Schlecht et al. 2007), 29% of 
42 head and neck squamous cell carcinoma (HNSCC) patients were tested positive for 
HPV16. When focused on never-smokers, out of the 123 genes that were identified with 
higher expression than HPV16-negative primary HNSCC tumours, SYCP2 expression had 
the highest fold change of over 120-fold (shown as the absolute difference in expression 
ratios in inverse log scale).  
 
A transcriptome analysis study (Masterson et al. 2015) carried out with a cohort of HPV-
associated oropharyngeal squamous cell carcinomas (OPSCC) patients identified SYCP2 
as one of the most upregulated genes in premalignant (carcinoma in situ) tissue, 
validated using real time quantitative polymerase chain reaction (RT-qPCR). A significant 




samples (log2 fold change of 1.8; P<0.01; 95 confidence interval [CI], 1.0-3.2). SYCP2 was 
included by The Wisconsin Alumni Group Foundation as one of the three potential 
biomarkers for OPSCC and precancerous lesions, along with STAG3 and testicular cell 
adhesion molecule 1, all of which exhibit testis-specific expression.  
 
SYCP2 was also detected as one of the upregulated genes in a genome-wide expression 
profiling study (Pyeon et al. 2007), including 56 head and neck and cervical cancers 
where 38% of head and neck cancers and approximately half of cervical cancers were 
HPV16-postive. Further analysis of SYCP2 in normal immortalised keratinocytes (NIKS) 
with HPV16 revealed an expression increase of >15-fold, in relative to HPV-negative NIKS. 
Knockdown of HPV16 E7 protein induced a significant decrease in SYCP2 expression 
relative to HPV16-postive NIKS. Interestingly, it did not result in the same expression 
level as HPV-negative NIKS, there was still approximately a 3-fold increase. The results 
suggested that SYCP2 expression was only partially induced by E7 (Pyeon et al. 2007).  
 
Furthermore, fold changes of SYCP2 expression (at the mRNA level) in primary cervical 
keratinocytes with E6 and E7 (delivered by recombinant retrovirus) were considerably 
higher than those with either one of the proteins expressed. This indicates a synergistic 
effect of E6 and E7 on SYCP2 expression. SYCP2 was also identified at the protein level 
in NIKS16 but not in NIKS, in parallel with the HPV16 E7 detection. However, it was not 
detected in CaSki, an HPV16+ cervical carcinoma cell line which had significant high level 
of HPV16 E7 protein (Pyeon et al. 2007). SYCP2 was also found to be among a set of 
genes that are consistently upregulated in HPV+ tumours, regardless of where they 





1.4 Gene silencing/editing mechanism 
1.4.1 RNA interference 
RNA interference (RNAi) is an evolutionary conserved strategy used by a range of 
organisms to induce gene silencing. mRNAs are targeted by double stranded RNA 
(dsRNA) homologs, ultimately leading to their degradation. This phenomenon was first 
described by Fire and Mello in their Nobel prize study on genetic interference by 
exogenous dsRNA in C. elegans (Fire et al. 1998).  
 
RNAi is divided into two main stages, the initiation, and the effector phase (Figure 1.4). 
In the first stage, dsRNA is cleaved in the cytoplasm by a specialised ribonuclease III-like 
enzyme called Dicer, resulting in a 21-23 nucleotides long dsRNA molecule, known as 
small interfering RNA (siRNA) (Lam et al. 2015). In the effector phase, siRNAs activate a 
multiprotein complex known as the RNA-induced silencing complex (RISC). The sense 
strand of siRNA undergoes cleavage by endonuclease argonaute 2 (component of RISC) 
and is disassociated from the complex, leaving the antisense (guide) strand attached to 
the RISC. Thus, the activated RISC is guided to its target mRNA sequence for cleavage 
and subsequent degradation (Agrawal et al. 2003; Petrova, Zenkova and Chernolovskaya 
2013). Binding only occurs with fully complementary mRNA, thereby allowing highly 















Due to its specificity, RNAi is regarded as a valuable tool in pharmacology and 
therapeutics. It has been introduced to patients with hereditary transthyretin 
amyloidosis where siRNA targets the liver (Setten, Rossi and Han 2019). Other uses of 
RNAi include gene expression analysis. In mammalian cells, RNAi can be stimulated by 
synthetically designed siRNAs that are 19-21 base pair in length. They essentially 
resemble the processed product by Dicer and can directly induce the effector phase. 
This feature allows RNAi to be utilised in targeted gene silencing for the study of 
expression and function. 
 
Figure 1.4 Mechanism of RNAi 
RNAi comprises of two stages, (A) initiation and (B) effector phase. The dsRNA molecule is broken 
down into smaller fragments via Dicer-mediated cleavage, resulting in formation of siRNAs. 
Subsequent RISC assembly and activation allows the complex (RISK/siRNA guide strand) to the 
mRNA targeted by the siRNA guide strand. Consequently, the mRNA undergoes cleavage and 





1.4.2 CRISPR/Cas9 genome editing technology 
Clustered regularly interspaced short palindromic repeats (CRISPR) along with CRISPR-
associated nuclease 9 (Cas9) is a versatile and rapid genome manipulation system with 
high precision. Type II prokaryotic CRISPR system uses Cas9 derived from Streptococcus 
pyogenes and is the most commonly used system, requiring the presence of a sole Cas9 
protein (Pellagatti et al. 2015). It is engineered and adapted from an ancient defence 
mechanism used by bacteria and archaea as part of their immune system. The 
mechanism allows the bacteria to defend against bacteriophages where they target and 
silence any detected foreign nucleic acid (Jinek et al. 2012).  
 
The Type II system comprises of an endonuclease (Cas9) and a base-paired scaffold 
termed guide RNA (gRNA), combined from a sequence-specific targeting component 
(crRNA) and a trans activating CRISPR RNA (tracrRNA) that links crRNA and Cas9 together 
(Costa et al. 2004). To date, the CRISPR/Cas9 system is the most efficient genome editing 
technology that is adaptable to a wide range of applications including gene therapy 
(Costa et al. 2004). 
 
In engineered CRISPR systems, the artificial gRNA is designed to contain a region of 
about 20 nucleotides at its 5’-end that is complimentary to the target DNA sequence. A 
conformational change of Cas9 protein is induced upon binding of gRNA, converting the 
Cas9 enzyme into its active form. The gRNA then directs the Cas9 to its corresponding 
protospacer adjacent motifs (PAMs) region (5’-NGG) that flanks the 3’-end of the target 
DNA sequence (Jinek et al. 2012). This allow the separation of DNA strands and 
subsequent binding between the complementary region of gRNA and the target strand. 




histidine-asparagine-histidine (HNH) domain and RuvC domain, respectively (Jinek et al. 
2012; Jinek et al. 2014).  
 
Subsequently, a blunt end DSB was generated and it can be repaired by either of the 
two pathways (Figure 1.5): non-homologous end-joining (NHEJ) or homology-directed 
repair (HDR). Without the presence of an exogenous homology repair template, DSB can 
be repaired though the error-prone NHEJ pathway, allowing random insertion/deletion 
mutations (indels) or replacement (Xiao, Guo and Chen 2019). Alternatively, a donor 
template can be provided which will allow precise gene editing that is essentially error-
free. Therefore, HDR can be used to induce a specific change within the target genome 
















Due to its simplicity and flexibility, the CRISPR-Cas9 system has been widely exploited in 
numerous gene function studies, inducing both loss of function and gain of function 
mutations. Beyond genome editing, removal of the catalytic activity of Cas9 by inducing 
mutation in the RuvC and HNH nuclease domain has allowed it to act as a recognition 
complex, as it maintains its ability to target specific DNA sequence. This function enables 
fusion with transcription activators or repressors to stimulate site-specific gene 
regulation (Pickar-Oliver and Gersbach 2019). 
Figure 1.5 Mechanism of CRISPR-Cas9 gene editing technology 
The CRISPR system composes of a Cas9 nuclease with a sgRNA complementary to the target 
sequence. Upon recognition, Cas9 induces DSB which can be repaired by either NHEJ or the HDR 
pathway. (Pellagatti et al. 2015) sgRNA = single guide RNA, DSB = double strand break, NHEJ = non-




1.5 Project outline 
The ectopic expression of SYCP2 in HPV+ cancers and the lack of information on this 
protein has led to the interest of this project, hoping to unravel the reasons and 
concepts behind this unusual observation. It is in the interest of this study to shed light 
on these two questions:  
1. What is causing SYCP2 expression in HPV+ cancers? 
2. What is the relationship between SYCP2 and HPV+ cancer cells? Do they require 
SYCP2 for survival? 
 
Upregulated SYCP2 expression in HPV+ cancer cells must be established as a starting 
point. This will be achieved by extracting RNA samples from seven cancer cells lines, five 
of which are HPV-positive and quantify expression level relative to housekeeping gene 
using qPCR. Three cell lines that demonstrate relatively high SYCP2 expression will 
undergo gene knockdown experiments to see the effect on cell viability using siRNA. 
Knockdown efficiency will be confirmed through qPCR.  
 
In addition, CRISPR/Cas9 genome editing technology will be used in wild type NIKS cells 
to induce random indels mutations with five set of gRNAs targeting at different SYCP2 
exon regions. The indels may cause frameshift mutations, leading to potential disruption 
in SYCP2 structure and function. Thereby allowing further examination of cellular 
responses to the loss of SYCP2. The plasmid contains green fluorescence protein (GFP) 
coding sequence, allowing the use of flow cytometry to sort and collect cells that were 






2 Materials and methods 
2.1 Tissue Culture 
2.1.1 Mammalian cancer cells 
All the mammalian cancer cell lines in Table 2.1 were cultured in Dulbecco's Modified 
Eagle Medium (DMEM) with L-glucose and 0.58g/L L-glutamine (Pan Biotech, #P04-
03550), supplemented with 5% foetal bovine serum (FBS) (Pan Biotech, #P30-3031) and 
with or without a mixture of 100U/mL penicillin and 100ug/mL streptomycin (Pan 
Biotech, #P06-07100) as required. Cells were maintained at 37°C with 5% CO2, media 
change were required every 48-72 hours. The culture was left to grow to required 
confluency before washed with 1X phosphate-buffered saline (PBS) (ThermoFisher, 
#BR0014G) and trypsinised using 0.05% Trypsin-EDTA (Pan Biotech, #P10-0235SP). 
Followed by inactivation of trypsin with DMEM containing FBS. Cells were then spun 
down at 300 G for 5mins and the resuspended cell pellets were plated into fresh culture 
flasks. 
 
Cell lines Cancer/Tissue of origin 
CaSki HPV16+ cervical squamous cell carcinoma 
HeLa HPV18+ endocervical adenocarcinoma 
UM-SCC-104 HPV16+ floor of mouth squamous cell carcinoma 
93-Vu-147T HPV16+ floor of mouth squamous cell carcinoma 
SiHa HPV16+ cervical squamous cell carcinoma 
PCI30 HPV- tongue squamous cell carcinoma 
C33a HPV- Cervical squamous cell carcinoma 









Mitomycin-C treated Murine 3T3-J2 fibroblast cells (known as feeder cells) were plated 
out at least 4 hours before they were co-cultured with NIKS cells. The NIKS were 
maintained in culture media which comprises of Ham’s F-12 medium (Pan Biotech, #P04-
14500) and DMEM with L-glucose and L-glutamine, at a ratio of 3:1, respectively. To this 
was added 5% FBS and with or without a mixture of 100U/mL penicillin and 100ug/mL 
streptomycin as required. The medium was supplemented with 24ug/ml adenine (Sigma, 
#A2786-5G), 8.3ng/ml cholera toxin (EMD Biosciences #227035), 5ug/ml insulin (Sigma, 
#I6634-50MG), 0.4ug/ml hydrocortisone (Sigma, #H0888-1G) and 10ng/ml epidermal 
growth factor (EGF) (Sigma, #E1257-0.1MG).  
 
NIKS were maintained at humidified atmosphere at 37°C with 5% CO2, media change are 
necessary every 24-48 hours. To prevent over-confluency, cells were passaged before 
80% confluency was reached. The flasks were washed with 1X PBS and incubated in 0.05% 
Trypsin-EDTA. As NIKS are more adherent to culture flasks than feeder cells, they remain 
attached to the surface while feeder cells became dislodged and removed. Second 
round of trypsinisation was performed to disassociate NIKS from tissue culture flasks. 
The cells were then spun down (at 300 G for 5 minutes) and the pellets were re-plated 
with newly cultured feeder cells.  
 
2.2 RNA and protein extraction 
Cells were harvested by washing the flask once with 1x PBS, followed by incubation with 
1 to 3ml of trypsin at 37°C. Required cell media containing FBS were added to the flasks 




300 G for 5 minutes. Media were aspirated and the cell pellets obtained were 
immediately placed on dry ice (known as snap freezing). On occasion where the pellets 
were required for RNA extraction, tissue culture flasks were directly placed on dry ice 
after washing and aspirated with cold 1x PBS. Both flasks and cell pellets were stored in 
-80°C freezer for downstream applications.  
 
Total cellular RNA was isolated from either cell pellets obtained from a T-25 flask or 6-
well plates (siRNA experiments) using New England BioLabs Monarch Total RNA 
Miniprep Kit (NEB, #T2010S), according to the manufacturer’s protocol. Cells from 6-
well plates were extracted using fresh cell scrapers. RNase-free DNase Kit (Qiagen, 
#79256) were used for DNA digestion during on-column RNA purification. Eluted RNA 
samples were stored at -80°C for quantitative polymerase chain reaction (qPCR) analysis. 
 
Protein samples were obtained from T-25 flasks using sterilised cell scrapers and 30-50ul 
of lysis buffer comprise of M-PER mammalian protein extraction reagent (ThermoFisher, 
#78501), 25x cOmplete protease inhibitor cocktail (Sigma, #04693116001), 20x 
PhosSTOP phosphatase inhibitors (Sigma, #04906837001) and Benzonase Nuclease 
(Sigma, #E1014-5KU) at 0.2unit/ul. Lysis buffer must remain on ice at all time. Cell pellets 
were directly resuspended in the lysis buffer. Sample were then transferred to a 1.5ml 
Eppendorf tube and lysed on ice for 20 minutes. Followed by centrifugation at 17,000 G 
for 15 minutes at 4°C to remove cell debris, and the supernatant containing protein were 







2.3 RNA analysis 
2.3.1 cDNA synthesis 
Concentrations of extracted RNA samples were quantified using the NanoDrop One 
Microvolume UV-Vis Spectrophotometer (ThermoFisher). Initially, up to 5μg/ul of total 
RNA were converted into complementary DNA (cDNA) using the GoScript Reverse 
Transcription System (Promega, #A5000), in accordance with the manufacturer’s 
instructions. Later in the project, LunaScript RT SuperMix Kit (NEB, #E3010L) was used 
instead due to higher conversion efficiency and reduced experiment time. All the 
experiments included a negative control with no reverse transcriptase present. 
 
2.3.2 Quantitative PCR 
All the qPCR reactions were comprised of 5ul PowerUp SYBR Green Master Mix 
(ThermoFisher, # A25918), 300nM (final concentration) of each forward and reverse 
primer, 2ul 10-fold diluted cDNA samples and required volume of deionised water to 
make a total reaction volume of 10ul. The assay was set up in 96-well plates using 
QuantStudio Design & Analysis software, with the cycle parameters shown in Table 2.2. 










Stages Temperature/°C Time Cycles 
Initial denaturation 95 10 min 1 
Denaturation 95 15 sec 40 
Annealing 60 1 min 
Melt curve 95 15 sec 1 
60 1 min 
95 1 sec 
Table 2.2 Cycle parameters for comparative and standard curve qPCR 
 
A negative control (of deionised water instead of cDNA) was included with each 
experiment. TATA-binding protein (TBP) was used as the control gene. All reactions were 
performed in duplicates and were repeated at least three times. Raw data (Ct value) was 
processed in Excel, where standard curve for each primer set were used to convert raw 
data into relative expression of transcripts for each gene that was analysed.  
 









E6 TCAGGACCCACAGGAGCG CCTCACGTCGCAGTAACTGTT Eurofin 

















2.4 Protein quantification and analysis 
2.4.1 Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Protein concentrations were quantified using the Pierce BCA Protein Assay Kit 
(ThermoFisher, #23227). Samples were prepared with 4x Laemmli sample buffer (final 
concentration of 240mM Tris-HCL pH6.8, 8% SDS, 40% glycerol and 0.04% bromophenol 
blue), 1M dithiothreitol and heated at 90°C for 11 minutes. Followed by SDS-PAGE ran 
on either 8% or 10% handcast polyacrylamide gels with Tris/Glycine/SDS running buffer 
containing 25nM Tris, 192nM glycine, 0.1% SDS, (pH 8.3) (BioRad). The gel percentage 
is an indication for the relative pore size of the polyacrylamide gel. The higher the 
percentage, the smaller the pores. Electrophoresis was carried out at 150v for 50 
minutes and protein samples were transferred from the gel to a Polyvinylidene 
Difluoride (PVDF) membrane using the Trans-Blot Turbo Transfer System (BioRad) 
according to the manufacturer’s protocol. The run time was extended to 12 minutes for 
proteins with high molecular wright. Whatman filter paper was shown to facilitate a 
complete transfer of the bands.  
 
2.4.2 Western blot analysis 
The membrane was blocked in 1x Tris-buffered saline (TBS) (pH7.6) with 0.1% Tween-
20 and 5% skimmed milk for 1-hr on a rocker at room temperature. Followed by 
overnight incubation with anti-SYCP2 primary antibody (1:250) (Abcam, #ab138562) on 
a rocker at 4°C. The PVDF membrane was then washed three times for 10 minutes each 
with TBS with 0.1% Tween-20 solution. Afterward, it was further incubated with 
horseradish peroxidase (HRP)-conjugated anti-rabbit secondary antibody (1:10,000) at 




for 10 minutes each with TBS with 0.1% Tween-20. Lastly, it was incubated with 
enhanced luminol-based detection (ECL) substrate (BioRad, #1705061), followed by 
protein detection on either a Syngene G:Box-fluorescence imager or using x-ray films. 
 
2.5 Generating standard curve for SYCP2 quantification 
2.5.1 Topo cloning 
Two primers targeted at a partial SYCP2 RNA sequence were designed on Integrated 
DNA Technology website (Table 2.4) with the aim to cover the transcript region targeted 
by SYCP2 qPCR primers. 
PCR 
Primers 












Table 2.4 Primers designed to use in Platinum SuperFi PCR 
 
Both primer sets were used with cDNA samples from the cell line UM-SCC-104 to amplify 
SYCP2 gene using Platinum SuperFi PCR Master Mix (Invitrogen, #12358010), in 
accordance with the manufacturer’s instructions. Blunt-end PCR products were 
generated which were then cloned into a plasmid (pCR-Blunt II-Topo), shown in Figure 
2.1 using Zero Blunt TOPO PCR Cloning Kit (Invitrogen, #K2800-20SC), according to the 















2.5.2 Bacterial transformation 
50ul of E. coli DH5-alpha competent cells (NEB, #C2987I) were thawed on ice for 20-30 
minutes, followed by addition of Topo plasmid containing SYCP2 gene. The 
microcentrifuge tube was incubated on ice for a further 20-30 minutes and then 
heatshocked for precisely 30 seconds at 42°C. Further 2 minutes on ice was required to 
enhance plasmid DNA entry. The outgrowth stage was performed with 250ul of SOC 
media for 1 hour in a 37°C shaking incubator. This enabled E. coli cells to establish 
kanamycin resistance via uptake of the Topo plasmid. Finally, different volumes (50-
150ul) of the mixture were plated out onto pre-warmed Luria Bertani (LB) agar plates 
containing 50µg/ml of kanamycin using sterile technique. The plates were incubated at 
37°C overnight. The kanamycin resistance gene in pCR-Blunt II-Topo acted as a selective 
marker for E. coli growth. Only the successfully transformed cells with their expressed 
resistance gene will result in colonies on the kanamycin agar plates. 
Figure 2.1 Map of pCR-Blunt II-Topo 
Genome map of Topo plasmid showing features including lac promoter/operator region at bases 
95-216, TOPO-Cloning site at bases 336-337, SP6 promoter priming site at bases 239-256, T7 
promoter priming site at bases 406-425 and kanamycin resistance ORF at bases 1237-2031 with 





2.5.3 Liquid culture and plasmid DNA purification 
Following successful transformation, single colonies were picked using sterile pipette tip 
and inoculated in a falcon tube containing 4ul of LB broth and 4ug/ml of kanamycin. The 
tubes were placed vertically in a 37°C shaking incubator for 18 hours with the speed of 
210rcf. After incubation, bacterial growth was characterised by the opaqueness of the 
media and plasmid purification was subsequently performed using QIAprep Spin 
Miniprep Kit (Qiagen, #27106), according to the manufacturer’s instructions. 
Concentration of extracted DNA were quantified using a NanoDrop One Microvolume 
UV-Vis Spectrophotometer. 15ul of DNA samples at 30ng/ul were sequenced using 
Sanger sequencing technology using standard primers from IDT, SP6 and T7.  
 
2.5.4 SYCP2 standard curve 
Miniprep sample with correct SYCP2 insert (confirmed by sequencing data) were used 
to generate SYCP2 standard curve using qPCR. With given total plasmid size (including 
SYCP2 insert) and concentration of the miniprep sample, concentration of plasmid 
required to have 108 copies/ul was determined. Followed by further calculation to result 
in a master plasmid stock of 109 copies/2ul. Seven individual samples were produced 
using serial dilution (1:10) with plasmid copy numbers going from 102 copies/2ul to 108 
copies/2ul. qPCR cycle parameters used are described in Table 2.2. Experiment was 
performed in triplicate wells in a 96-well plate and repeated three times. The average 
threshold cycle (Ct) value was plotted against the dilution factor and the data was fitted 
to a straight line to give the standard curve. The linear equation of the plot was then 
used to determine the relative copy level of a given gene in unknown samples 




2.6 RNA interference with siRNA 
2.6.1 Reverse transfection of siRNA 
Each experiment consists of mock, control siRNAs and SYCP2 siRNA in triplicates and was 
repeated at least three times. All siRNAs used were provided by Horizon Dharmacon and 
are presented in Table 2.5. For each well, 0.2ul of 20uM siRNA stock was diluted in 19.8ul 
of Opti-MEM (ThermoFisher, #31985062). In mock transfected wells, equal volume of 
Opti-MEM was added instead of the siRNA. A master mix was made with 0.2ul of 
Lipofectamine RNAiMAX Transfection Reagent (Invitrogen, #12323563) and 19.8ul of 
Opti-MEM per well. 5 minutes incubation at room temperature was required to allow 
the mixing of reagents, followed by the addition of 20ul of Opti-MEM. 40ul of the master 
mix was added to each well to reach a final siRNA concentration of 20nM. The plate was 
then shortly spun on PlateFuge Microcentrifuge (Benchmark Scientific), followed by 
incubation at 37°C for 30 minutes. Cells seeded in a T25 flask with 60-80% confluency 
were passaged, counted, and added at a concentration of 2000 cells per well in 140ul of 
DMEM without antibiotics.  
 
On day 5 post transfection (given that day 0 is transfection day), cell viability assay was 
performed to assess transfection efficiency. Media were aspirated and replaced with 
100ul of DMEM/5% FBS without antibiotics. To this was added 20ul of CellTiter 96 
AQueous One Solution (Promega, #G3582), followed by incubation at 37°C for 2.5 hours 
and absorbance reading at 490nm using a CLARIOstar microplate reader (BMG 
LABTECH). Data normalisation was performed against triplicates of blank wells 





 Table 2.5 siRNAs used in reverse siRNA transfection 
 
2.6.2 Forward transfection of siRNA 
Cell suspension from reverse transfection were used for seeding cells for forward 
transfection. 300,000 (SiHa) – 400,000 (UM-SCC-104 and 93Vu-147T) cells were seeded 
into a 6-well plate in 2.5ml of DMEM/5% FBS without antibiotics. This occurred 48 hours 
(SiHa and UM-SCC-104) or 72 hours (93-VU-147T) prior to forward transfection, allowing 
the culture to reach 60-80% confluency. On the transfection day, 5ul of Lipofectamine 
RNAiMAX was combined with 245ul of Opti-MEM in a microcentrifuge tube and was 
allowed to incubate for 5 minutes at room temperature. 3ul of 20uM siRNA stock 
(negative control and SYCP2) was added to 247ul of Opti-MEM in a separate 
microcentrifuge tube. siRNA was replaced with equal volume of Opti-MEM in mock 
transfections. They were performed to determine non-specific effects that may have 
resulted from the transfection reagents or the experiment. The two tubes were 
combined and incubated at room temperature for 30 minutes. Finally, the mixture is 
added to the 6-well plates to which a media change was carried out on the day, this 
results in a final siRNA concentration of 20nM. Cells were harvested 48 hours post 
transfection by snap freezing the 6-well plates after it was rinsed with cold 1x PBS. RNA 





siRNAs Catalogue number (Horizon) 
ON-TARGETplus Non-targeting Control D-001810-01-05 
SMARTpool: ON-TARGETplus SYCP2  L-020632-00-0005 




2.7 CRISPR knockout in NIKS 
2.7.1 gRNA and vector construct 
Five gRNA designs (provided by Horizon) were used in this project (Table 2.6), each 
targeting different SYCP2 exon regions as illustrated in Figure 2.2 













gRNA catalogue number gRNA name used Sequence (5’-3’) 
SYCP2_147644 gRNA 4 ACCTGGAGATCTGGTCTTAT 
SYCP2_147645 gRNA 5 AAATATATTTCTCTAGCAGT 
SYCP2_147646 gRNA 6 ATATAAGGTTGTCCACCTTG 
SYCP2_147647 gRNA 7 ATTTCAGGAACTTAATAAAG 
SYCP2_147648 gRNA 8 CCACAATGTTTCAGCCATTT 
Figure 2.2 Linear map of SYCP2 genome with gRNA positions 
SnapGene revealed that exon 3 is targeted by gRNA 4, gRNA 5 and 6 both target exon 4 and gRNA 



































Vector pD1301-AD (provided by Horizon) was used in this project for the delivery of 
SYCP2 CRISPR-Cas9 system (shown in Figure 2.3). It contains two separate promoters, 
human U6 and cytomegalovirus (CMV), which regulates the expression of SYCP2 gRNAs, 









Figure 2.3 Genome map of pD1301-AD with SYCP2 gRNA insert 
The vector provided by Horizon comprises of 9042bp, with CRISPR-Cas9 system and GFP gene 
included in the construct. Ori_pUC acts as the origin of replication. Promoter hU6 regulates gRNA 
expression and Cas9 is controlled by promoter CMV.  Presence of GFP gene allows positive 
selection for desired insertion and successful transfection. The vector also comprises of an NLS 
sequence, allowing import of proteins into the cell nucleus. Kanamycin resistance gene allows 









2.7.2 NIKS transfection 
Wild type (wt) NIKS were maintained as described in section 2.1.2. Typically, the cells 
were seeded 24-48 hours before transfection, allowing 70-80% confluency on the day 
of transfection. The experiments were carried out in T25 flasks using FuGENE HD 
Transfection Reagent (Promega, #E2311) and following the FuGENE HD Technical 
Manual. Briefly, 18ul of transfection reagent and 6ug of DNA (plasmid containing CRISPR 
gRNA) was needed per T25 flask with, giving a ratio of 3:1, respectively. Required volume 
of Opti-MEM was added to provide a total volume of 300ul. The transfection mixture 
was incubated at room temperature for 15mins before it was added to the T25 flasks 
containing newly added antibiotics-free FC media. The culture was incubated at 37°C 
with 5% CO2 and imaged 48h post transfection using a fluorescence microscope to 
estimate transfection efficiency. 
 
2.7.3 Flow cytometry 
Cell were sorted for GFP signal 48h post transfection using BD FACSJazz flow cytometer 
(BD Biosciences). Prior to sample preparation, the machine was set up and calibrated, 
along with correctly aligned lasers and streams. Once the machine is ready, the cells 
were trypsinised as previously described in section 2.1.2 but the cell pellets were 
resuspended in 1ml of 1x PBS instead. The samples were loaded into round-bottom 
polystyrene capped falcon tubes and kept on ice to prevent aggregation. Wt NIKS were 
used to determine background signal due to cell autofluorescence during sorting. The 
sample tubes were placed into the FACSJazz machine and the GFP-positive cells were 
sorted by creating gates outside of the autofluorescence seen in wt NIKS cells. The 




were maintained at 37°C with 5% CO2. Data obtained were analysed using the BD FACS 
Sortware software. 
 
2.7.4 DNA extraction 
After passaging post-sorted NIKS cells into T25 flasks, they were allowed to grow to 80% 
confluency before been used to generate frozen stocks and DNA samples. Cell 
suspensions were divided into two falcon tubes before centrifugation. One tube was 
resuspended in freezing media containing 10% dimethyl sulfoxide, followed by aliquots 
into cryovials for storage at -80°C. The other cell pellet was resuspended in 180ul of 1x 
PBS and DNA extraction was performed using the QIAamp DNA Mini Kit (Qiagen, 
#51306), in accordance with the manufacturer’s instructions. Followed by quantification 
using a nanodrop spectrophotometer. DNA of wt NIKS was also extracted in the 
procedure.  
 
2.7.5 Identification of indels with next generation sequencing (NGS) 
Requirement for sequencing includes designing primers with incorporated Nextera 
universal sequencing adaptor, producing amplicons that are approximately 200 base 
pairs (bp) in length with the CRIPSR cut site located in the middle. PCR amplification of 
extracted DNA and purification is subsequently performed. Identification of indels were 
carried out using Illumina Miseq Sequencing at UCL Cancer Genome Engineering Facility 
and further sequencing analysis were performed using CRISPR-PARSR pipeline created 
by Dr Javier Herrero from UCL Cancer Institute. Finally, a gene editing report is produced 
containing information on percentages and locations of indels and the genome editing 




2.7.5.1 Primers design 
Suitable forward and reverse primers with an overhang universal adaptor sequence at 
its 5’-end (illustrated in Figure 2.4) were designed using SnapGene software. All primers 
were tested for formation of dimers and hairpin/secondary structures using an online 
primer structure analysis tool on the IDT website (http://eu.idtdna.com/calc/analyzer). 
Sequences of primers are shown in Table 2.7.  
 






















































2.7.5.2 PCR amplification  
Using the primers in Table 2.7 and extracted DNA samples, amplicons were produced 
using KAPA HiFi HotStart ReadyMixPCR Kit (KAPABiosystems, #KK2600). The volume of 
components was scaled accordingly to give a final volume of 10ul, as presented in Table 
2.8. PCR conditions used in this project is described in Table 2.9. A gradient of annealing 
temperature was used to determine the optimised condition for each amplicon. Total 
of four primer set were used with five DNA samples, generating four amplicons with 
sizes presented in Table 2.7.  
Components Volume/ul Final concentration 
2X KAPA HiFi HotStart 
ReadyMix 
5 1X 
10uM forward primer 0.3 0.3 uM 
10um reverse primer 0.3 0.3 uM 
DNA  As required 100ng/ul 
PCR-grade water As required N/A 
Table 2.8 KAPA PCR mixture 
 
 
Stages Temperature/°C Time Cycles 
Initial denaturation 95 3 min 1 
Denaturation 98 20 sec 30 
Annealing 58-62 15 sec 
Extension 72 15 sec 
Final extension 72 1 min 1 


















2.7.5.3 Generation and purification of amplicons 
Following PCR reactions, gel electrophoresis was performed with 1ul of product to 
establish initial assessment of amplification specificity. 1ul of 6x DNA loading dye was 
added to the product and loaded onto 2% DNA agarose gel with 100bp plus DNA ladder 
(NEB). Gel electrophoresis was performed at 100V for 32-35 minutes. Upon detection of 
single bands with corresponding amplicon sizes, the remaining 9ul of PCR product was 
combined with 2ul of 6x loading dye and gel electrophoresis was repeated. Each band 
were then cut out and purified using Monarch DNA Gel Extraction Kit (NEB, # T1020L), 
according to the manufacturer’s instruction. 1ul of purified sample were ran on the gel 
to show single product with no other bands due to primer dimer formation, a gel image 
was attached with the NGS request form. Purified DNA samples were quantified using a 
nanodrop spectrophotometer and were submitted for NGS with a total volume of 20ul 






















3.1 Establishment and optimisation of quantification assay for SYCP2 
3.1.1 Successful gene cloning 
Miniprep samples from eight liquid cultures were amplified via PCR using SYCP2 qPCR 
primers (Table 2.3), followed by gel electrophoresis. This allowed the initial assessment 
of gene cloning success. A single band was detected around 100bp for all miniprep 
samples, corresponding to the qPCR product size of 105bp for SYCP2. Subsequently, the 
samples were sequenced, and the results obtained indicated successful gene cloning for 
three out of the eight samples (Figure 3.2). Sequencing data for M1 (primer set 1) is 
shown in Figure 3.2b where there was an exact sequence match with the product that 
is generated by primer set 1 (Figure 3.2a). Hence, M1 (primer set 1) was used to carry 







Primer set 1 Primer set 2 
M1 M2 M3 M4 M1 M2 M3 M4 
Figure 3.1 Gel electrophoresis of miniprep samples resulted from Topo PCR cloning 
Four miniprep samples (denoted as M) were obtained for each primer set designed (Table 2.4). 
Gel electrophoresis was performed (2% gel, 100V for 35mins) after PCR amplification using 1ul of 
PCR product and 1ul of 6X DNA loading dye. 5ul of 100bp DNA ladder was loaded in lane 1. Single 





























Figure 3.2 Illustration of partial SYCP2 sequence and corresponding sequencing data 
Partial SYCP2 sequence is shown with (a) red and blue nucleotides corresponding to primer set 1 
in Table 2.4, giving a PCR product size of 417bp. The highlighted green and purple sequences refer 
to the forward and reverse SYCP2 qPCR primers, respectively (Table 2.3). In (b), sequencing data 
of M1 (primer set 1) using SP6 primer revealed exact match of nucleotides seen in (a), indicating 















































Figure 3.3 Standard curve for SYCP2 qPCR primers 
Linear equation (y=-3.394x + 37.146) was generated using average Ct values from repeated 





























Triplicate repeat of standard curve qPCR assay was performed with M1 (primer set 1) to 
generate a standard curve for SYCP2 quantification at the mRNA level. A repeated qPCR 
assay data is shown in Figure 3.4 which demonstrated the data points used for standard 
curve was reliable as the technical repeats for each plasmid concentration gave identical 
or similar Ct values. The melt curve plot illustrated correct amplification of SYCP2 
transcript in samples with different plasmid concentration. High primer efficiency was 
demonstrated for all three targeted genes analysed in this project (Table 3.1). 
 
Figure 3.4 Amplification and melt curve plot for miniprep sample using qPCR 
The amplification plot revealed a calculated threshold level of 0.099901, corresponding to the 
cycle number in which a significant amount of SYCP2 transcript was accumulated. Sample 1 to 7 
in the melt curve plot corresponds to the different plasmid concentrations, ranging from 102 





The linear equation from Figure 3.3 was used to convert raw data (Ct value) into SYCP2 
transcript copy number. The following calculation was performed using Excel: 
 y(Ct) = a + b * x (log10 copy number)   
       
a = y-intercept  
b = slope gradient 
 Log10 copy number = (Ct – a)/b 
 
 
 Copy number = 10^ (log10 copy number)  
 
 
E6 standard curve was obtained by carrying out qPCR assay as described in section 2.5.4, 
using plasmid (pLXSN, 5874bp) with E6 insert (477bp) provided by Dr Tim Fenton. 
Standard curve for TBP was generated by Dr Nerissa Kirkwood, member of Tim Fenton’s 
research group. Linear equations for SYCP2, TBP and E6 primers are presented in Table 
3.1 and were used throughout this project to calculate SYCP2 and E6 expression level 
relative to TBP.  
 
qPCR primer targeted genes Linear equation Primer efficiency/% 
TBP y = -3.217x + 36.555 104 
SYCP2 y = -3.394x + 37.146 99 
E6 y = -3.611x + 38.404 89 











3.2 Validating SYCP2 overexpression 
SYCP2 overexpression was established via comparative qPCR, using housekeeping gene 
TBP expression as a control. A threshold level was calculated by the QuantStudio Design 
& Analysis software and the results obtained were given in Ct (threshold cycle) values. 
This reflects the cycle number at which a significant number of amplicons has 
accumulated, providing sufficient fluorescence to cross the threshold value. Average Ct 
values from triplicate repeats were converted into expression values using the standard 
curve generated for SYCP2 qPCR primers and are shown in relative to TBP expression 
level. 
 
HPV16 positive cell lines all demonstrated increased SYCP2 expression levels relative to 
TBP (Figure 3.5a), with 93-Vu-147T cell line exhibiting the highest value of 2.7 (copy 
number relative to TBP). Notably, SYCP2 expression in HeLa cells (HPV18 positive) was 
not higher than that seen in the HPV negative cell lines, PCI-30 and C33a, suggesting 
SYCP2 upregulation is only seen with certain high-risk HPV types. SYCP2 expression 
levels observed in HPV+ cell lines may be low compared to E6 copy number relative to 
TBP (Figure 3.5b) but nevertheless, approximately 16- to 30-fold increase was 
demonstrated when compared to the HPV- cell lines, with 93-VU-147T showing almost 
30-fold increase compared to PCI-30. One way ANOVA test showed a statistically 
significant difference for relative SYCP2 expression level between all HPV16+ cell lines 






Further qPCR assays were carried out in HPV16+ and HPV- cell lines with E6 as the gene 
of interest (Figure 3.5b), as an approach to observe if the expression level of SYCP2 was 
related to E6 expression. It is clear that E6 expression level is significantly higher than 
SYCP2 across all HPV16+ cell lines, with CaSki, UM-SCC-104, 93-VU-147T and SiHa 
showing over 550-, 220-, 160- and 45-fold increase compared to PCI-30, respectively. 
One way ANOVA test demonstrated significant difference for CaSki (p <0.0001), UM-
SCC-104 (p <0.01) and 93-VU-147T (p <0.04) but not SiHa. As expected, the HPV- cells 
lines do not show any E6 expression. From these results, we can see that the level of 
SYCP2 expression is not directly correlated with the level of E6 expression HPV16+ 
cancer cell lines; rather, it would appear that all of the HPV16+ lines, regardless of their 
E6 expression level, have strongly upregulated SYCP2 expression. 
Figure 3.5 Expression of SYCP2 and E6 relative to TBP in RNA samples extracted from HPV+/HPV- 
cancer cell lines 
Average expression of (a) SYCP2 and (b) E6 relative to TBP were gathered from triplicate repeats of 
qPCR. One way ANOVA statistic tests were performed between HPV+ cell lines and PCI-30 in both 
















3.3 Effect of siRNA gene silencing on cell viability 
3.3.1 MTS assay for siRNA transfection efficiency  
The established ectopic expression in HPV+ cancers has led to an assumption of possible 
dependency between cell survival and SYCP2 levels. Three cell lines (93-VU-147T, UM-
SCC-104 and SiHa) with relatively high SYCP2 expression (see Figure 3.5a) were selected 
to undergo siRNA transfection. To assess the cellular effect of gene silencing, cell 
viability assay (MTS) was performed on day 5 of reverse siRNA transfection (given 
transfection occurs on day 0) in 96-well plates. It is a colorimetric assay that is based on 
the ability of metabolic active cells to reduce the tetrazolium dye 3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) to a purple 
coloured formazan, thereby reflecting the number of viable cells present. The 
absorbance was read at 490nm using a spectrophotometer, providing quantitative data.  
 
Inhibits of polo-like kinase 1 (PLK1) protein have detrimental effects on cell cycle 
progression, leading to apoptosis and disruption of mitosis in cancers. Hence PLK1 siRNA 
was used as a positive control in this experiment. Non-targeting (NT) siRNA designed not 
to target any known mRNAs, was used as negative control to allow detection of non-









































Figure 3.6 Microscopic images of siRNA transfected UM-SCC-104 cells on day 2 and day 5 post 
transfection 
UM-SCC-104 cells were imaged at 100x magnification on day 2 and day 5 post transfection. Figure 
(a) to (d) represent mock, NT, PLK1 and SYCP2 siRNA-transfected cells, respectively, with day 2 
designated as (1) and day 5 as (2). Significant low number of viable cells can be seen in the PLK1-
transfected population compared to other siRNA transfected cultures. Viability does not seem to 































Figure 3.7 Microscopic images of PLK1 transfected 93-VU-147T and SiHa cells on day 5 post 
transfection 
On day 5 post transfection, (a) 93-VU-147T and (b) SiHa cell lines showed significant low number of 
viable cells in the PLK1-transfected population. 
(b) 
 
Figure 3.8 Percentage of viable cells post-siRNA transfection using MTS assay 
Illustration of viable cell percentages using MTS assay on day 5 post transfection. (a) Viability of 
three HPV16+ cell lines transfected with mock, control and SYCP2 siRNAs are shown. In (b), SYCP2 
data were normalised with normalised percent inhibition (NPI) calculation, using NT as the upper 






Microscopic images of 93-VU-147T and SiHa (Figure 3.7) cell lines also demonstrated a 
low number of viable cells in the PLK1-silenced populations, as shown for UM-SCC-104 
cell line in Figure 3.6. In addition, average of <5% cell viability was calculated for PLK1-
silenced cells for all three HPV+ cell lines (Figure 3.8a). This result suggested that siRNA 
transfection efficiency was reasonably high in the experiments performed. Viability for 
SYCP2-silenced cells remained high, surpassing the value for cells transfected with NT 
siRNA. SYCP2 data was normalised against NT and PLK1 as upper and lower bound, 
respectively (Figure 3.8b). Resulting NPI data also demonstrated high viability 

















3.3.2 Confirmation of gene silencing via qPCR 
RNA samples with insufficient concentration was extracted from reverse siRNA 
transfected cells in 96-well plates, leading to the application of 6-well plates using 
forward siRNA transfection (as described in 2.6.2). In this experiment, components were 
scaled up to give a final siRNA concentration of 20nM. The results (Figure 3.9) showed 
that approximately 50% gene silencing was achieved in all three cell lines, by comparing 
the relative SYCP2 expression level between mock and SYCP2-silenced cells. One-way 
ANOVA statistic test indicated that 93-VU-147T showed the most significant knockdown 
of SYCP2 gene. Some significant difference was detected in SiHa, whereas UM-SCC-104 










Figure 3.9 Relative SYCP2 expression in three siRNA transfected HPV+ cell lines 
RNA samples were extracted from transfected cells in 6-well plates 48h-post transfection, 
followed by cDNA synthesis and qPCR. Data are shown from repeated (n=4) forward siRNA 
transfection. One-way ANOVA statistic test was performed between mock and NT/SYCP2 values, 
no significant difference was observed between the mock transfected and NT transfected cells in 
all three cell lines. 93-VU-147T showed the most significant difference between mock and SYCP2 
transfected cells with a value of p <0.001. UM-SCC-104 showed no statistic significant (p <0.1) and 














The effect of gene silencing using siRNA was undeniably noticeable as presented in 
Figure 3.9, where the relative SYCP2 expression seen in SYCP2-silenced cells 
substantially decreased. However, full SYCP2 knockdown was not achieved in this 
experiment as the relative expression level was still above (with 5-7 fold differences) 












Figure 3.10 Relative SYCP2 expression level in HPV+/HPV- cell lines and siRNA transfected 
HPV16+ cell lines 
Comparison of SYCP2 expression level (relative to TBP) between HPV+/HPV- cell lines and the 




3.4 Generation of Indels using CRISPR-Cas9 system 
3.4.1 Purity and sequences of gRNAs 
Concentration for each gRNA-containing plasmid was determined using a nanodrop 
spectrophotometer. Measurements of A260/A280 ratio above 1.80 and A260/A230 
above 2.0 indicated DNA purity for all samples (Table 3.2). 
Table 3.2 DNA concentration and purity of Horizon SYCP2 gRNAs miniprep 
 
Confirmation of gRNA sequences was achieved through Sanger sequencing (Figure 3.11). 
The data showed perfect match against the reference sequences in Table 2.6, therefore, 
CRISPR knockout experiment was proceeded using these five gRNAs. 
SYCP2 gRNA designs Concentrations(ng/ul) A260/A280 A260/A230 
gRNA 4 85 1.86 2.23 
gRNA 5 95 1.87 2.22 
gRNA 6 95 1.86 2.28 
gRNA 7 91 1.86 2.26 

























Figure 3.11 Chromatogram data of gRNA sequences 
The data confirmed the correct sequence for all five gRNA designs, with (a) to (e) representing 




























Figure 3.12 Evaluation of CRISPR transfection in NIKS under fluorescence microscope and 
assigned gates in FACS 
Wt NIKS was used in flow cytometry (a) to establish background signal due to autofluorescence 
and figure (b) to (f) represents gRNA 4 – 8 transfected cell population, respectively. The upper 
panel shows fluorescence microscope image taken 48hr post transfection and the bottom panel 
shows the gate that was assigned for sorting GFP-positive cells. Approximately 10,000 events 
occurred with each cell sample. Green cells were not detected in wt NIKS cells (not shown) but are 
visible in gRNA transfected cell populations. Cells with fluorescence signal outside of the 
autofluorescence seen in wt NIKS (indicated by P2) were sorted and collected. A noticeable peak 








The fluorescence microscope images identified many GFP-positive cells under blue light 
for all gRNA transfected cell populations (Figure 3.12), suggesting great success in 
delivery of CRISPR-Cas9 system in NIKS cells. However, a peak towards the end of the 
graph was visible in all transfected populations (lower panels of Figure 3.12) but was not 
detected in the wt population. Possibly due to the voltage been set too high during 
sorting, which caused the GFP-positive cells to pile up at the far end of the scale. 
 
Cells with GFP-positive characteristics were sorted/collected and plated into 6-well 
plates, allowing recovery, growth, and DNA extraction of edited cell population. 
However, it is not guaranteed that the cells collected were all effectively inserted with 






















3.4.3 Amplification and purification of DNA from edited cell population 
PCR were performed with parameters from Table 2.9 to establish the optimised 
annealing temperature for each amplicon product. It was concluded that 60°C was best 
for amplicon 1 and 58°C for the other three set of amplicons generated from gRNA 
transfected cells, as determined in Figure 3.13. All four amplicons were also produced 
from wt NIKS cells (with annealing temperature of 58°C), showing single band around 
300bp (Figure 3.13 and 3.14). 
Figure 3.13 Gel electrophoresis of amplicon products from DNA amplification  
Total of four set of amplicons were produced with gRNA 7 and 8 producing the same amplicon.  
DNA from wt NIKS were amplified with primers for amplicon 1. 1ul of PCR product with 1ul of 6x 
DNA loading dye were loaded into each well on a 2% agarose gel. It ran for 35mins at 100V with 
5ul of 100bp DNA ladder in lane 1. Single band between 200 and 300bp was detected in all 
























Figure 3.14 Gel electrophoresis of amplicon products from wt NIKS  
Amplicons 2 – 4 were amplified using wt NIKS DNA samples with an annealing temperature of 
58°C. 1ul of PCR product with 1ul of 6x DNA loading dye were loaded into each well on a 2% 
agarose gel with a running time of 35mins at 100V. 5ul of 100bp DNA ladder was loaded in lane 1. 
Single band was detected for all amplicons around 300bp.  
Figure 3.15 Gel electrophoresis of purified amplicons 
1ul of purified DNA sample with 1ul of 6x DNA loading dye were loaded into each well on a 2% 
agarose gel, with a running time of 35mins at 100V. 5ul of 100bp DNA ladder was loaded in lane 
1. Single band between 200 and 300 bp was detected for all amplicons generated from gRNA 





Subsequently, gel electrophoresis was performed with the best optimised amplicon 
products generated from all five gRNAs (as highlighted in Figure 3.13) and wt NIKS 
(Figure 3.13 and 3.14). The single bands were extracted and purified, preventing the 
samples from containing any unspecific DNA molecules such as those due to primer 
dimer formation. Gel electrophoresis was repeated with 1ul of purified product (Figure 
3.15) and an image was attached with the request form for targeted next generation 
sequencing (Illumina Miseq). 
 
3.4.4 Next generation sequencing analysis 
Gene editing efficiency of individual gRNAs was obtained from Miseq sequencing data 
(Figure 3.16).  As indicated, gRNA 5 – 8 did not generate high frequency of indel 
mutations, which resulted in high wild type reads from the edited cell population.  In 
contrast, gRNA 4 demonstrated a high percentage of SYCP2 indels. However, these 
mutations occurred within a region that is upstream of the gRNA cut site where it 
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Figure 3.16 Gene editing efficiency of gRNAs  
Results from Miseq sequencing analysis are presented as percentages of indel mutation due to 
delivery of CRISPR-Cas9 system to NIKS cells. gRNA 4 seems to demonstrate the most efficient 






Miseq sequencing data for gRNA 4, 5, 7 and 8 showed poor gene editing efficiency with 
mutations occurring at non-gRNA cut site, gRNA 4 is shown as an example in Figure 3.17. 
Therefore, these data will not be further investigated in this project. Only gRNA 6 
showed potential gene editing within the gRNA cut site. 261 deletion events occurred at 
110bp with a single deleted G nucleotide, as illustrated in Figure 3.18. Wt NIKS cells did 
not display indel mutations at the gRNA 6 cute site (Figure 3.19), thereby indicating 
successful CRISPR activity. However, the cell population overwhelmingly consisted of 
wild type (17,294 reads), suggesting poor editing efficiency. Hence, single cell cloning 
was not carried out. 
 
 
Figure 3.17 Illustration of the most common indel mutations generated by gRNA 4 and its 
corresponding target sequence and cut site  
Three of the most common deletions and insertions occurred at 63bp where the repeating T 
nucleotides are found. The mutated site is upstream of the gRNA 4 target sequence as shown in 
SnapGene. No indels were observed at the gRNA cut site.  
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Figure 3.18 Illustration of the most common deletions generated by gRNA 6 and its 
corresponding target sequence and cut site  
Most frequent deletions (total of 291 events) occurred around gRNA 6 cut site as indicated o 
SnapGene software. Including 261 single nucleotide (G) deletions and 30 of 4-nucleotide (ACAA) 
deletions. 
gRNA 6 cut site 
 
Figure 3.19 Miseq sequencing data of amplicon 3 for wt NIKS cells 
No indel mutations were generated at the gRNA 6 cut site for wt NIKS cells that was not transfected 
with gRNA 6. 
 




























CRISPR analysis provided graphic information on the size, location, and midpoint of most 
common indel mutations generated. Due to poor gene editing efficiency, only the 
location of gRNA 6 induced deletion is presented (Figure 3.20). Sequence alignment of 
the single nucleotide deletion using SnapGene revealed a frameshift mutation, causing 
an alteration in the amino acid sequence, as illustrated in Figure 3.21. 
Figure 3.20 Graphic presentation of the most common deletions in cell population transfected 
with gRNA 6 
 
Figure 3.21 The consequence of single nucleotide deletion within SYCP2 gene 
Single nucleotide deletion seen with gRNA 6 was revealed in SnapGene to induce a frameshift 
mutation immediate downstream of the cut site, causing incorrect translation of the genetic code. 






4.1 SYCP2 mRNA is upregulated in HPV16+ cell lines 
SYCP2 is a protein predominant found in the testes that is known to localise within the 
SC structure and contribute towards the organisation of chromosomal axis during 
meiotic prophase I. The ectopic expression of SYCP2 in HPV+ cancers has consequently 
led to the interest of this project, with the aim to elucidate whether knockout of SYCP2 
expression could influence cancer cell viability. 
 
The first objective was to validate the findings established in several HPV-related cancer 
studies, where significant SYCP2 upregulation was shown. qPCR data collected from this 
project demonstrated a substantial increase of relative SYCP2 expression level in 
HPV16+ cancer cell lines in comparison to HPV- cell lines. Almost 30-fold increase was 
seen in 93-VU-147T and 20-fold with CaSki and SiHa compared to the HPV- cell lines, 
PCI-30 and C33a (Figure 3.5a). The HPV- cell lines showed almost no expression of SYCP2. 
In a study (Martinez et al. 2007) carried out with squamous cell carcinoma of the head 
and neck (SCCHN) patients identified SYCP2 as one of the upregulated genes in both 
HPV+ versus HPV- SCCHN and HPV+ SCCHN versus normal oral tissues analysis. Together 
with data from Figure 3.4a suggests a strong correlation between HPV status and SYCP2 
expression, however the mechanism is yet to be understood.  
 
Interestingly, HeLa (HPV18+) showed little or no SYCP2 expression, corresponding to the 
unpublished RNAseq and DNA methylation data from a study (Fenton. T) where high 




possible indication for the existence of some key cellular differences between the 
genotypes. One of which could be the ability to upregulate SYCP2 expression. 
 
Deregulated E6 and E7 expression are the fundamental events that drive malignancy in 
high risk HPV infections. Mainly through inactivation of tumour suppressor proteins and 
disruption of cell cycle progression (Xu et al. 2013). Figure 3.5b shows that all HPV16+ 
cell lines exhibit high E6 expression. In particular, CaSki showed over 500-fold increase 
in E6 copy number relative to TBP compared to HPV- cell lines. In contrast, SiHa only 
revealed approximately 50-fold increase in E6 copy number ( Meissner 1999; Sahab et 
al. 2012;Xu et al. 2013). These data correspond to the HPV16 status of each cell line, 
CaSki has about 600 HPV16 copies per cell whereas SiHa only has 2 integrated copies of 
HPV16 genome. No apparent correlation can be drawn between the expression of E6 
and SYCP2 in HPV16+ cell lines. For instance, CaSki demonstrated highest E6 level 
compared to other three cell lines but it is not resembled in the SYCP2 data. Furthermore, 
SiHa displayed similar SYCP2 level as CaSki despite being the cell line with the lowest E6 
expression. However, it could be the case that a threshold level of E6 is required to 
induce SYCP2, thus SYCP2 expression plateaus once the threshold is reached. Expression 
of individual HPV proteins in NIKS could be performed to clarify if E6 expression has a 









4.2 Cell viability is not affected by SYCP2 gene knockdown 
The effect of SYCP2 knockdown in HPV16+ cell lines did not seem to impact the cell 
viability as determined by MTS assay. In fact, higher percentage of viable cells were 
measured in SYCP2-silenced population compared to the culture transfected with NT 
siRNA (Figure 3.8a) which acts as a negative control. It should be noted that a significant 
decrease in cell viability was seen in NT relative to mock transfection. This indicate that 
the NT siRNA could be toxic, possibly due to off-target effects which caused cell death. 
Therefore, a different NT siRNA could be used in future work to prevent similar 
observation. Approximately 20% difference was observed between NT and SYCP2 data 
in all three HPV16+ cell lines. However, in some replicates, the cell viability percentages 
between NT and SYCP2 transfected population showed little or almost no differences. 
The variation in data is most likely caused by frequent occurrence of freeze-thaw cycle, 
leading to reduced siRNA efficiency. Both graphs in Figure 3.8 seems to suggest that 
silencing of SYCP2 gene improves the growth and survival of HPV16+ cancer cells.  
 
Microscope image of SYCP2 transfected UM-SCC-104 culture on day 5 post transfection 
(Figure 3.6) showed high similarity with the mock transfected population. This cell line 
tends to grow collectively in colonies which is displayed in both mock and SYCP2 
transfected culture. In contrast, no colonies were seen in PLK1-silenced population 
(Figure 3.6c2) and majority of cancer cells were deteriorated with visible damaged cell 
membrane. Low viable cell percentage for PLK1-transfected population in all cell lines 
(Figure 3.8a) was a clear indication that high transfection efficiency was achieved. Both 




to imply that the knockdown of SYCP2 expression does not have a negative effect on 
cancer cell viability. In fact, enhanced growth and survival seems to be more of the case.  
 
Same concentration of siRNA was used in both quantification assays (MTS and qPCR) to 
allow direct analysis of gene knockdown for each cell line (Figure 3.9). The ON-TARGET 
siRNAs from Horizon were advertised to provide successful gene silencing at 75% or 
above. However, only about 50% gene knockdown was achieved in all tested cell lines. 
They still expressed SYCP2 at a level higher than HPV- cell lines (Figure 3.10). This 
reduction of mRNA level may not be sufficient to fully conclude the effect of SYCP2 
knockdown on HPV+ cancer cell viability. Transfection efficiency was not a limiting factor 
as PLK1 data in Figure 3.8a demonstrated strikingly high knockdown percentages. 
Frequent freeze-thaw cycle could again cause this poor knockdown of SYCP2 gene. 
However, it is unlikely to be the main contributing factor because similar knockdown 
efficiency was observed in experiments performed using new aliquots of SYCP2 siRNA.  
 
4.3 Possible mechanism for SYCP2 expression in HPV+ cancers 
4.3.1 Epigenetic regulation  
The precise mechanism and function of CTA expression in cancer remains poorly 
understood, but there have been many proposed theories such as epigenetic 
abnormality. A previous study (Litvinov et al. 2014) documented aberrant CTA 
expression in cutaneous T-cell lymphoma patients and discovered that inhibition of 
histone deacetylation resulted in significant upregulation of CTA mRNA level, including 
SYCP1. Cells treated with histone acetyltransferases inhibitors produced the opposite 




treatment resulted in downregulation of SYCP1 at the protein level. It was highlighted 
that many meiotic genes tend to undergo extensive post-translational regulation to 
ensure stability and facilitating different stages of spermatogenesis (Bettegowda and 
Wilkinson 2010). These combined results demonstrate a potential mode of regulation 
for CTA expression. Unpublished data from Tim Fenton observed a strong reduction in 
the methylation of multiple CpG sites in the SYCP2 promoter in HPV16+ but not HPV18+ 
or HPV25+ cervical cancers. Therefore, suggesting that the methylation status of SYCP2 
promoter plays a potential role in inducing expression in HPV16+ cervical cancers.  
 
Demethylation is another epigenetic event that regulate the expression of many genes, 
including INK4A–ARF which expresses a tumour suppressor protein named p16INK4A. It is 
a critical regulator for cellular senescence. This gene is normally repressed in healthy 
cells by the presence of H3K27me3 (histone H3 lysine 27 trimethyl) mark, however it 
becomes activated upon cellular stress (Agger et al. 2009; McLaughlin-Drubin, Crum and 
Münger 2011). HPV16 E7 oncoprotein has been demonstrated to associate with a 
member of the E2F transcription factor family, E2F6 to induce the expression of two 
histone demethylases, KDM6A and KDM6B. E2F6 is a transcription repressor and a 
component of the polycomb transcriptional repressive complexes that associate with 
silenced chromatin (McLaughlin-Drubin, Huh and Münger 2008). KDM6B is responsible 
for the demethylation of H3K27m3 in HPV+ cancers that result in the expression of 
p16INK4A. High p16INK4A level is frequently found in HPV-related cancers such as cervical 
carcinomas. Thus, it is recognised as a biomarker for cervical cancers. Furthermore, a 
significant reduction of H3K27m3 mark was shown in primary human foreskin 
keratinocyte (HFK) with HPV16 E7 expression. Whereas no detectable changes were 




A study (McLaughlin-Drubin, Park and Munger 2013) performed with HPV16+ cell lines 
including CaSki and SiHa demonstrated a dramatic decrease in cell proliferation/survival 
when KDM6B level was depleted. Ectopic expression of HPV16 E7 in HFK with depleted 
KDM6B also showed a striking decrease in cell viability. Hence, it was concluded that the 
KDM6B addiction in cervical cancer cells was a direct consequence of HPV16 E7 
expression. Therefore, demethylation of SYCP2 promoter via this mechanism could 
potentially be responsible for the aberrant expression in HPV16+ cancers. However 
further investigations will be required to elucidate this theory. 
 
4.3.2 Genomic instability  
As mentioned previously, SYCP2 is an important component of the SC structure which 
ensures high-fidelity meiotic segregation of homologous chromosome during prophase 
I. Ectopic expression of SYCP2 in HPV-positive cancers including OPSCC, HNSCC and 
cervical squamous cell carcinoma (CSCC) likely contribute to genomic instability 
which is a hallmark of cancer (Guo et al. 2014; L. Costa, Boroni and Soares 2017). This 
characteristic allows cancer progression and prevent immunologic and pharmacologic 
eradication.  
 
A review (Lindsey et al. 2013) described possible consequences of meiotic gene 
expression in mitotic cells. In particular, SYCP1 was one of the genes that were expressed 
in melanomas and it may contribute to chromosomal missegregation and genomic 
instability. The review particularly focused on other meiotic proteins such as SPO11 and 
REC8. REC8 is a meiotic-specific cohesin protein that replaces mitotic protein RAD21. 




formation, homologous recombination, and adhesion between sister chromatids. 
Overexpression of REC8 in mitotic cells has been noted to cause chromosome 
segregation defects (Ishiguro et al. 2010).  
 
Studies have shown that SYCP3 expression in mitotic cells seems to inhibit an important 
component of the homologous recombination (HR) repair pathway, BRCA2. In addition, 
it caused cells to confer hypersensitivity to poly(ADP-ribose) polymerase (PARP) 
inhibitors (Hosoya et al. 2011; Hosoya and Miyagawa 2014). This characteristic is 
commonly observed in cancer therapy with PARP inhibitors for BRCA1/BRCA2 deficient 
tumours. Generally, cells respond to DNA damage such as DSBs by activating BRCA2 (a 
tumour suppressor protein) which recruits a protein called RAD51 to the DSB site, where 
it is loaded onto single-stranded DNA to promote homologous DNA paring. However, 
when SYCP3 is expressed, the HR pathway is disrupted and consequently causing DSB 
accumulation which ultimately leads to genomic instability. This finding provided a 
potential mechanism for chromosomal instability seen in cancers with SYCP3 
overexpression. Thereby it would be interesting to investigate if the HR pathway is also 
impaired/altered in HPV+ cancers with aberrant SYCP2 expression. 
 
A study (Li, Bolcun-Filas and Schimenti 2011) demonstrated that SYCP3-decifient female 
mice produced viable oocytes but often with aneuploidy features. It was discovered that 
the expression of DNA meiotic recombinase 1 (DMC1) and TRIP13, proteins normally 
required for HR repair of meiotic DSBs, is deemed non-essential for oocyte survival in 
the absence of SYCP3 and SYCP2.  This bypass involves a protein, DNA repair and 
recombination protein RAD54 (RAD54) that stimulates inter-sister chromatid 




arrest if inter-homolog repair of DSBs were prevented, proving that normal oocytes can 
only repair meiotic DSBs via recombination between homologous chromosomes, and 
not via recombination between sister chromatids. However, if SYCP2 or SYCP3 
expression is disrupted, then the oocytes survived. It was concluded that the surviving 
oocytes were able to repair their DSBs via inter-sister recombination. Therefore, SYCP2, 
SYCP3 or both must act to prevent inter-sister recombination and repair. This could 
explain why HPV16 induce SYCP2 expression, inter-sister recombinational repair of the 
host genome would be prevented and thus maintaining the G2 arrest state, allowing 
viral amplification. 
 
HPV E6 and E7 expression was established in a study (Wallace et al. 2017)to hinder the 
HR repair pathway. It promoted the initiation of HR at particular cell cycle stages where 
the sister chromatids were unavailable to serve as a homologous template. Furthermore, 
E6 was capable of preventing RAD51 recruitment to both persistent and transient DSB 
sites. Consequently, the inability to repair DSBs would cause persistent lesions in cancers, 
which is a common phenotype observed in tumours with increased integration of HPV 
genome. However, it was also demonstrated that both HPV16 oncogenes stimulated 
expression of RAD51 and BRCA2 which are components of the HR pathway. Therefore, 
it was suggested that E6 and E7 promote initiation but inhibit the full completion of HR. 
This was based on previous findings showing increased level of RAD51 localisation at the 
HPV replication foci upon genome amplification (Gillespie et al. 2012), implicating the 
need for HR protein during the viral productive phase. Although full investigation has 
not been previously carried out on SYCP2 overexpression, the research on meiotic-
specific genes such as SYCP3 may provide a fundamental platform for uncovering 




4.4 Application of CRISPR-Cas9 system in NIKS cells  
CRISPR-Cas9 system is a highly feasible and flexible gene editing technology, with great 
specificity at the DNA level. Allowing targeting of given sequences at any locus. Hence it 
has been widely used in cancer biology to screen for any cancer-related genes and 
establishing protein function through knockout mutations (Wang et al. 2014). Complete 
SYCP2 knockdown in NIKS cells using CRISPR were subsequently performed after 
insufficient knockdown percentage in siRNA experiments. NIKS cells were used in this 
project for their non-tumorigenic feature whilst maintaining normal cell-type-specific 
growth in monolayer culture (Allen-Hoffmann et al. 2000). They also exhibit limitless 
capacity to proliferate due to their immortalised state.  
 
A study (Yamano, Dai and Moursi 2010) has reported on the transfection efficiency of 
FuGene HD reagent in different cell lines, including several cancer cells lines, stem cells 
and primary human epidermal keratinocytes. Only 2-5% efficiency was achieved in 
transfection of β-Galactosidase to primary human epidermal keratinocytes. Whereas, 
20-35% was seen in HeLa cell line. Overall, FuGene HD transfection reagent was proven 
to exhibit high transfection efficiency.  
 
Five set of gRNAs were designed to contain sequences complementary to exon 3, 4 and 
5. The aim was to generate random indel mutations and cause disruption in SYCP2 
structure and function through the NHEJ DNA repair pathway. Followed by generating 
single cell clones with desired indel mutations. However, none of the gRNA successfully 
induced indel mutation at the gRNA cut site with sufficient editing efficiency. Only gRNA 




accomplished with over 17,000 wt read. Therefore, single cell cloning was not 
proceeded due to the process being time-consuming with little chance of success.  
 
Chromatin status has been found to relate to CRISPR transfection efficiency. The 
prokaryotic origin of Cas9 nuclease may prevent its full operation in different eukaryotic 
chromatin structures due to the fundamental differences. Evidence has shown that 
longer scanning time is required when the target site is hidden within heterochromatin 
compared to euchromatin where the site is more accessible by Cas9 (Uusi-Mäkelä et al. 
2018; Verkuijl and Rots 2019). In addition, a study (Hinz, Laughery and Wyrick 2015a) 
has shown that the catalytic activity of Cas9 significantly decreased when the PAM motif 
was localised within the nucleosome compared to if it was situated in the more 
accessible DNA linker region. Hence, it was speculated that more inhibitory effect will 
be displayed at higher-order chromatin structure. Findings have suggested that off-site 
target binding strongly correlates with the accessibility of chromatin and gRNAs are 
known to vary widely in their off-target binding frequency (Kuscu et al. 2014; Hinz, 
Laughery and Wyrick 2015b). These combined results demonstrated the positive 
correlation between open chromatin state and gRNA targeting efficiency. Hence, it is 
possible that the SYCP2 gRNA target sites were buried within the closed chromatin in wt 
NIKS, which impeded the accessibility of Cas9 to its relevant DNA cut site.  
 
Flow cytometry was performed post transfection to produce a sorted population 
containing GFP-positive cells. The FACS data (Figure 3.12, bottom panels) showed a peak 
towards the end of the plot for all gRNA transfected cells, which is not seen in the wt 
NIKS population. Therefore, it was speculated that the voltage was set too high during 




population. This indicates that the cells were sorted due to autofluorescence instead of 
GFP signal. Hence, this would explain the observed data where the sorted population 
contained primarily of wt NIKS for all gRNAs.  
 
CRISPR transfection was attempted again but due to unavailability of the equipment, 
the post transfection cell samples remained unsorted. Regardless, DNA was still 
extracted with the intention to send the unsorted samples for NGS analysis. Due to the 
time constraints of this project, the NGS report will not be incorporated in this project, 
however it would allow the project to proceed in the future by providing some insight 



















4.5 Established quantification assay for SYCP2 mRNA 
This project successfully established a novel quantification assay for SYCP2 at the mRNA 
level. 100% amplification efficiency is achieved when the amount of molecule of the 
target sequence doubles during each amplification cycle. The SYCP2 standard curve 
generated displayed 99% primer efficiency, indicating appropriate melting temperature 
and great primer design with no formation of secondary structures such as dimers and 
hairpins. Therefore, it was redeemed acceptable to apply the SYCP2 standard curve in 
qPCR analysis.  
 
Other analysis method includes the ∆∆CT tool which can be used to compare target gene 
expression in relation to other selected genes. The data obtained is presented in fold 
changes. This method was initially used in this project, where SYCP2 expression in HPV+ 
cell lines was displayed as the number of fold changes it is increased by when compared 
to HPV- cell lines. However, the collected data showed significant variation between 
repeated experiments. Therefore, the standard curve was generated as a new 
quantification assay. It is a particularly useful tool that allows direct comparison of 
SYCP2 expression with normalisation to housekeeping genes such as TBP between any 
cell lines or primary cells. It also allowed us to check the efficiency of SYCP2 primers. The 
process may be time-consuming, but the standard curve can be used in any future work 
and allows direct comparison with the results collected from this project. Furthermore, 
the procedure described in section 2.5 can be adapted to generate standard curve for 






4.6 Conclusion and future directions  
4.6.1 Conclusion 
To recapitulate, whilst protein expression was unable to be established in HPV16+ cell 
lines, SYCP2 was shown to be overexpressed at the mRNA level, which was quantified 
using the standard curve generated. This corresponds to the studies on HPV+ cancers 
where SYCP2 was identified as one of the genes that were upregulated in relation to 
HPV- cancers (Pyeon et al. 2007; Schlecht et al. 2007; Masterson et al. 2015).  The 
inability to induce complete knockdown in siRNA transfection despite high PLK1 
efficiency raised an interesting assumption.  
 
Unfortunately, CRISPR knockout in NIKS cells were not successful, possibly due to the 
inaccessibility of chromatin structure or high voltage during cell sorting. Nonetheless, 
some level of CRISPR knockout was seen with gRNA 6, where indel mutations were 
detected within the target cut site, causing frameshift mutation with altered amino acid 
sequence. This could possibly hinder the cellular function of SYCP2. However, low 
editing efficiency prevented further experiments such as generating single cell clones. 
In conclusion, with better understanding and clarification of the mechanism responsible 
for aberrant SYCP2 expression in mitotic cells and cancer cells, it would allow the 
development of potential novel biomarkers for several HPV-induced cancers and be 







4.6.2 Future directions 
If SYCP2 is deemed as critical for cellular survival, then it would be possible that cells 
with silenced SYCP2 gene would display reduced viability. Hence it would be interesting 
to attempt knockout in HPV+ cell lines such as SiHa and UM-SCC-104 with known SYCP2 
expression. Followed by direct comparison with the qPCR data collected from this 
project to show if SYCP2 depletion has any negative effect on cancer cell survival.  
 
SYCP2 protein expression has not yet been fully confirmed in previous study (Pyeon et 
al. 2007), possibly due to protein instability which leads to intrinsic degradation. 
Treating the HPV+ cancer cells with membrane permeable proteasome inhibitors such 
as MG132 could resolve the degradation issue and confirm the protein expression using 
Western blot analysis (Yong et al. 2009).  
 
Previous study demonstrated that E7 knockout in NIKS with HPV16 showed partially 
reduced SYCP2 expression when compared to NIKS with HPV16 (Pyeon et al. 2007). This 
indicated the induction effect of HPV16 E7 on SYCP2. Therefore, E6 knockout could also 
be tested in HPV+ cells lines to see if it demonstrates similar effect. In addition, 
combined knockout would allow the confirmation of synergistic effect of E6 and E7 
induction on SYCP2 expression. Upon obtaining knockout models, E6/E7 expression can 
be re-introduced to see if SYCP2 expression returns to the level detected in HPV16+ 
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